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EXECUTIVE SUMMARY
Development and Evaluation Of An Opioid Monitoring Clinic
By
Richard Luna Talusan
Dr. Jennifer Kawi, Examination Committee Chair
Assistant Professor, School of Nursing
University of Nevada, Las Vegas

An APRN-led Opioid Monitoring Clinic was developed and implemented in the
primary care setting of Las Vegas’ Department of Veterans Affairs in July 2013 to assist
primary care providers (PCP) in the management of high risk patients on chronic opioid
therapy for chronic noncancer pain. The clinic assisted in monitoring patients for abuse
and misuse of opioids and referred patients for treatment when abuse and misuse were
discovered. A study to evaluate the OMC was undertaken from November 22, 2013
through February 23, 2014 to assess the effectiveness of the OMC in meeting its
objectives. A total of 61 patients and 26 PCPs participated in the study. The OMC was
able to identify 26 patients who were abusing and misusing their prescription opioids that
resulted in the discontinuation of their opioid therapy and referral for treatment. The
study also found improved compliance among PCPs in following recommendations from
the VA/DoD clinical practice guideline in the management of chronic pain using opioid
therapy. All PCPs who referred patients to the OMC reported overall satisfaction in
having the OMC co-manage their patients on chronic opioid therapy.
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CHAPTER 1
INTRODUCTION
According to the International Narcotics Control Board (2013), the United States
continue to face an opioid prescription drug abuse problem that threatens its public health
system. The use of opioids in the management of chronic, noncancer pain, has become
too common in the United States that the nation has become the number one prescriber of
opioids in the world with about 200 million prescriptions of opioids written in 2009
(Volkow, McLellan, Cotto, Karithanom, & Weiss, 2011). The United States with only
5% of the world population is estimated to consume about 56% of the world’s supply of
opioid medications (International Narcotics Control Board, 2013). For example, a more
striking statistic is that the United States consumes 99% of the world’s supply of
hydrocodone and 83% of world’s supply of oxycodone (Manchikanti et al., 2012). These
statistics are despite the fact that long term use of opioids in the management of chronic
pain is becoming more controversial especially with the lack of solid evidence of its
effectiveness in the management of chronic noncancer pain and due to its associated long
term adverse effects like addiction, abuse, and misuse of opioids (Krebs, Ramsey,
Miloshoff, & Bair, 2011; Manchikanti et al., 2012).
Birnbaum et al. (2011) reported that about 5-10% of total healthcare spending
dealing with chronic pain was spent on care related to opioid abuse and misuse. In 2007,
the United States healthcare system spent $55.7 billion on care of patients who abused
opioids. The prevalence of opioid abuse/misuse in the United States has been estimated
at around 4-26% (Von Korff, Kolodny, Deyo, & Chou, 2011). Among veterans, the
prevalence of abuse and misuse of opioids has been reported at around 18-32% (Ives et
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al., 2006; Krebs et al., 2011; Reid et al., 2002). Even though the Department of Veterans
Affairs has large purchasing power in negotiating down drug prices, in 2013 the Southern
Nevada Healthcare System (VA-Las Vegas) dispensed nearly 700 million pills containing
opioids amounting to nearly $90 million in opioid related pharmaceutical cost. This
accounts for nearly 12,000 pills for each veteran enrolled in the VA Las Vegas.
The focus of this project was the development and the implementation of an
Opioid Monitoring Clinic (OMC) as a clinical referral service within the Primary Care
service of the VA-Las Vegas which already had an approved policy for the development
and implementation of this OMC (See Appendix A). The project also involved a study to
evaluate the effectiveness of the OMC in meeting its goals and objectives.
The growing problem with chronic use of opioid therapy in the management of
chronic pain includes addiction, diversion of opioids, and drug overdose (Manchikanti et
al., 2012). Compliance with the recommendations from evidenced-based clinical practice
guidelines has been asserted as sound mitigation strategy to assist healthcare providers in
their decision making process in preventing abuse and misuse of opioids that can
potentially reduce opioid-related complications (Trescot et al., 2006). To assist with
compliance with using the clinical practice guideline for chronic opioid therapy, the
OMC provided regular monitoring of patients to help identify abuse and misuse of
prescription opioids. The strategies involved in the operation of the OMC may also
benefit the general public by reducing and/or stopping the diversion of opioid
prescriptions written and dispensed for patient use from reaching other people who may
not be familiar with its use which can lead to harm from opioid-related complications
such as accidental overdose.
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The VA has a specific clinical practice guideline recommended to healthcare
professionals for the use of opioids in chronic pain. The collaborative clinical practice
guideline from the Department of Veterans Affairs and Department of Defense
(VA/DoD), VA/Dod Clinical Practice Guideline For Management Of Opioid Therapy
For Chronic Pain, was originally developed in 2003 and later revised in 2010. This
guideline recommends trial of opioids to patients with moderate to severe pain who have
failed to adequately respond to non-opioid and non-drug therapy in the management of
chronic noncancer pain. Additionally, this clinical practice guideline recommends
routine urine drug screening (UDS) for patients on chronic opioid therapy to screen for
presence of illegal drugs, minimal or avoidance of short acting opioids for breakthrough
pain (instead, conversion from short to long acting opioids to reduce potential for abuse
or misuse of opioids and to help maintain stable analgesic affect), and avoidance of
opioid use on patients with active opioid misuse or abuse (Department of Veterans
Affairs and Department of Defense, 2010).
Problem Statement
Reports of opioid abuse and misuse among patients are common in both
commonplace readings such as local newspapers as well as in professional, peerreviewed journals. Reports of addiction to prescription opioids, opioid diversion to
support an addiction to other illicit substances, and opioid-related complications such as
opioid-related deaths are unfortunately fairly common nowadays. Additionally, reports of
prescribers abuse in illegally or illegitimately writing opioid prescription to people who
may or may not be their patients are serious problems that contribute to an epidemic level
of prescription opioid abuse (Federation of State Medical Boards, 2013; SAMHSA,
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2011). Further, studies have shown that many prescribers of opioids are not following
current guidelines in the long term use of opioids for the management of chronic
noncancer pain (Starrels et al., 2011). A survey of all PCPs in the VA-Las Vegas showed
that more than one third (38%) of all PCPs were not familiar with the guideline; and for
those who were familiar with the guideline, more than a quarter (28%) were not
following the guideline. Further, the survey showed that all (100%) PCPs who responded
indicated that they and/or their patients were likely to benefit from an opioid monitoring
clinic to assist them in the management of patients on chronic opioid therapy for chronic
noncancer pain.
Purpose Statement
The purpose of this project was to develop an OMC in VA-Las Vegas for
intensive monitoring of opioid use to help identify veterans who abuse and/or misuse
their opioids. Once patients were evaluated and admitted in the OMC, veterans’ opioid
use was strictly managed by the OMC. The OMC handled the renewal, dose adjustment,
opioid substitution, and opioid discontinuation, if needed. Additionally, veterans
admitted in the OMC underwent intensive monitoring for abuse and misuse of opioids
and other illicit substances. Patients’ chronic opioid therapy was aligned with the current
VA/DoD clinical practice guideline for the management of chronic pain using opioid
therapy. The OMC assisted PCPs, through several educational presentations, in
identifying veterans at high risk for opioid abuse and/or misuse based on published data
of characteristics of these patients. Published reports showed that patients with history of
substance abuse including alcohol, cocaine, heroin, and marijuana were considered high
risk individuals (Ives et al., 2006; Manchikanti et al., 2012; Starrels et al., 2011;
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Wiedemer, Harden, Arndt, & Gallagher, 2007). Furthermore, patients who consistently
tested negative for prescribed opioids were also identified as high risk individuals for
misuse or diversion of opioids (Becker, Meghani, Barth, Wiedemer, & Gallagher, 2009;
Meghani, Wiedemer, Becker, Gracely, & Gallagher, 2009; Wiedemer et al., 2007;
Worley, 2014; Worley & Hall, 2012).
Project Objectives
The following were the project objectives: (1) Develop an Opioid Monitoring
Clinic as a referral service within the VA Primary Care Service Line, (2) Implement risk
reduction strategies in the OMC for patients admitted to the OMC, and (3) Evaluate
OMC effectiveness as far as ability to identify misuse/abuse of opioids through
implemented risk reduction strategies, pharmacy cost reduction for opioid use, increased
provider satisfaction, and improved PCP compliance with VA/DoD clinical practice
guideline.
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CHAPTER 2
REVIEW OF LITERATURE
In 1997, the average sales and distribution of opioids in the United States was
96mg morphine equivalents per person. Morphine equivalent is a calculated approximate
morphine dose of the opioid prescribed to the person per day. For example, a
Hydrocodone 10/325mg is equivalent to 10mg of oral morphine (McAuley, 2013, April
18).
In 2000, when the Joint Commission on the Accreditation of Healthcare
Organizations (The Joint Commission) started recommending that pain level be the 5th
vital sign, the average sales and distribution of opioids jumped to 710mg morphine
equivalents per person. The Joint Commission recommendation increased awareness in
the right to pain relief which may have inadvertently resulted in the significant increase in
the use of opioids in the management of pain (Manchikanti et al., 2012; Phillips, 2000).
According to the Substance Abuse and Mental Health Services Administration
(SAMHSA), there are approximately 12 million people in the United States who abuse
and misuse prescription opioids by using them for nonmedical reasons or by obtaining
opioid painkillers without a legitimate prescription and using them for nonmedical
reasons. Annually, the prevalence rate of Americans who abuse and misuse opioids is
around 2 million people (SAMHSA, 2011). Despite the growing problem with opioid use
in the United States, there is still a current prevailing thought among patients and
healthcare providers that the use of opioids in chronic non-cancer pain is highly effective
and carry little adverse effect to patients (Manchikanti et al., 2012). Even when opioids
are used according to accepted prescribing guidelines, many adverse effects have
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occurred including death due to overdose and other inappropriate use of opioids.
Inappropriate use of opioids includes opioids obtained through drug diversion (giving or
selling opioids to others). In 2010, 75% of all people who died from prescription drugs
died from opioid overdose. Nearly 17,000 people died of opioid overdose in 2010 that
the number of opioid-related deaths continues to outpace the number of people dying
from a motor-vehicle for persons 34-54 of age (Jones, Mack, & Paulozzi, 2013). The
number of unintentional opioid-related overdose death has more than tripled since 1990
(Figure 1).

Figure 1. Opioid-related overdose deaths from 1990-2008. (CDC, 2011,
November 1). Retrieved from
http://www.cdc.gov/homeandrecreationalsafety/rxbrief/

According to the SAMHSA, more than 12 million people reported using opioids
for purposes other than management of pain (SAMHSA, 2011). The Centers for Disease
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Control and Prevention has declared that abuse of prescription opioids in the United
States has reached epidemic proportions; and that the number of nonmedical users of
prescription opioids has equaled or exceeded the number of users of marijuana (CDC,
2013, July 2; Heit & Gourlay, 2010). Ives et al. (2006) reported in their prospective
study that about a third of patients with chronic pain on chronic opioids misuse their
opioids. Another report estimated that 1 in 3000 patients who have been exposed to
opioids will develop drug aberrant behaviors that place them at high risk for abuse and
misuse of opioids (Cepeda, Fife, Chow, Mastrogiovanni, & Henderson, 2012). Further,
those with history of substance abuse were at much higher risk of abuse or misuse of
opioids than those with no history of substance abuse (Fishbain, Cole, Lewis, Rosomoff,
& Rosomoff, 2008).
Injudicious prescription of opioids among healthcare providers is often cited as a
contributor to the growing problem of opioid abuse and misuse in the United States
(Federation of State Medical Boards, 2013). Healthcare provider knowledge in the
proper and judicious use of opioids in the management of chronic pain is crucial in
reducing the complications of chronic opioid therapy (Federation of State Medical
Boards, 2013; Manchikanti et al., 2012). One way to assist healthcare providers in their
decision making in the management of patients with chronic pain is through the use of
clinical practice guidelines. A clinical practice guideline is defined as, "systematically
developed statements to assist practitioner and patient decisions about appropriate
healthcare for specific clinical circumstances"(Field & Lohr, 1990). Clinical practice
guidelines are formulated based on best practices that focus on patient safety and
effectiveness of clinical decisions. However, Krebs et al. (2011) reported that there is a
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lack of compliance with the VA/DoD guideline for opioid use among providers who
write opioid prescriptions to veterans with chronic pain. Poor compliance with evidencebased clinical practice guidelines such as guidelines from the VA/DoD and the joint
guidelines from the American Pain Society and the American Academy of Pain
Physicians may have an impact in the high rate of accidental death from opioid overdose
among veterans (Bohnert, Ilgen, Galea, McCarthy, & Blow, 2011). Further, poor
compliance with evidenced-based clinical practice guidelines my exacerbate the problem
with opioid abuse and misuse among patients at high risks for opioid abuse and misuse.
Reid et al. (2002) reported that 31% of veterans on chronic opioid therapy for chronic
noncancer pain in their study were found to be abusing and/or misusing opioids. The
percentage of veterans abusing and misusing their opioids in the Reid et al. (2002) study
was similar to findings by Von Korff et al. (2011) which reported an opioid abuse and
misuse rate of nearly 30% among patients on chronic opioid therapy for chronic
noncancer pain. A more recent study by Baser et al. (2013) found that the five year
prevalence rate of opioid abuse and misuse among veterans on chronic opioid therapy for
chronic noncancer pain was 3.26%, and that the prevalence of opioid abuse among
veterans is nearly 7-fold as compared to the general population. This is noteworthy
because many patients are often continued on opioid therapy for many years and thereby
increasing their risk of abuse and misuse of their prescription opioid as they accumulate
years on chronic opioid therapy. In fact studies have shown that it becomes very difficult
for patients to come off opioid therapy once they start on it. A study by Martin et al.
(2011) reported that once a patient is on opioid therapy for at least 90 consecutive days,
the chance of them being on continued opioid therapy in their lifetime remained high;
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50% of patients in their study remained on opioid therapy years after the start of opioid
therapy.
The consequential economic cost for chronic pain is substantial. The annual cost
is estimated to be between $560-635 billion; and about $99 billion of the total economic
cost for chronic pain is spent by the Federal and State governments (Gaskin & Richard,
2012). In 2007, $55.7 billion was spent on care of patients who abused opioids
(Birnbaum et al., 2011). Leider, Dhaliwal, Davis, Kulakodlu, and Buikema (2011)
reported that patients with chronic pain who abuse and misuse opioids spent 35% more
time in the hospital with 14% higher healthcare costs than those who do not abuse and
misuse opioids. Patients who misuse opioids had an average excess medical cost of
$20,546 per year as compared to those who do not misuse opioids (Birnbaum et al.,
2011). The economic burden among veterans is even higher. A recent report by Baser et
al. (2013) reported that the annual economic cost of veterans who abused their opioid
prescriptions was nearly $29,000.
The incidence of opioid abuse and misuse is high resulting in exorbitant
healthcare costs. Opioid abuse and misuse are also major patient safety issues with
ramifications that can extend to the welfare of the public. In 2010, 12 million reported
misusing their opioid prescriptions by using their pain medications for nonmedical
reasons (SAMHSA, 2011). For example, people who misuse their opioid prescriptions
may mix their prescription opioids with alcohol and/or other illicit substances such as
cocaine, heroin or marijuana to support their addiction. Another example of opioid
misuse is the diversion of prescription opioids by sharing their opioids with friends
and/or families or by selling their opioids to other people (Manchikanti et al., 2012). In
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2008, nearly 15,000 people died from opioid overdose and according to the CDC, this
number was higher than the number of people who died from cocaine and heroin
combined (CDC, 2011, November 1). Patients who misuse opioids can be challenging to
PCPs as these patients present with aberrant behaviors that tend to stress the resources of
clinicians and organizations. Worley (2014) reported that patients who go from provider
to provider to obtain opioid prescriptions tend to exhibit behaviors that can be
psychologically draining to clinicians.
The high prevalence of death from opioid abuse and misuse, the reported
epidemic of people who use their opioids for nonmedical reasons, and the high economic
cost for people who abuse and misuse their opioids are serious concerns not just for the
VA but for the entire nation as well. Based on these evidence-based problems, a need for
innovative solutions is much needed. The OMC is an innovative approach to help solve
this serious problem. To my knowledge, based on published literature, the OMC is the
first opioid monitoring clinic for high-risk patients on chronic opioid therapy in the VA
and in the United States that was developed, implemented and operated by an advanced
practice registered nurse (APRN).
Opioid renewal clinics have been implemented in the VA in the past but none
were directly operated by an APRN. In 2002, a clinic called Opioid Renewal Clinic
(ORC) was implemented in the Philadelphia VA to assist PCPs in the management of
patients with chronic pain and on chronic opioid therapy (Wiedemer et al., 2007). The
ORC was a collaborative co-management between PCPs and pharmacy service. The
pharmacy service assisted in ordering and documenting the monitoring of patients
referred to the ORC and the PCPs were still responsible in renewing the opioid
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prescriptions of patients enrolled in the ORC. The two year pilot study accepted a total
of 335 patients. The authors reported that 51% of patients accepted in ORC initially had
documented aberrant behaviors and 45% of these patients resolved their aberrant
behaviors through intensive opioid monitoring using random urine drug testing.
Furthermore, the authors suspected that the 38% of patients who eventually discharged
themselves out of the ORC likely had an ongoing addiction or were diverting opioids.
The authors suspected that by discharging themselves out of the ORC, they may be
protecting their addiction and/or opioid diversion from being caught in the ORC.
Thirteen percent (13%) of patients who were accepted in the ORC were found to have an
addiction problem with opioid use and eventually were referred to addiction treatment;
and 4% were weaned off opioids due to consistently negative urine drug screens. The
ORC demonstrated significant pharmacy cost savings, increased use of urine drug
screening by PCPs, decreased emergency room visits, and increased PCP satisfaction.
A VA in Ohio created the Controlled Substance Oversight Board (CSOB) to
assess compliance of opioid management practice per current VA/DoD clinical practice
guideline and created an opioids refill clinic for renewing opiods for veterans. Patients
who were identified as abusers and misusers of opioids were convicted for drug
trafficking; and those who did not participate in the recommendation of CSOB were
flagged by the CSOB to alert staff of their noncompliance with recommended treatment
(Climer, n.d.). A VA in New York was able to reduce opioid cost by effectively
switching veterans on more expensive long acting opioids such as Oxycontin and
Fentanyl to less expensive long acting opioids such a long acting morphine. A secondary
purpose of this initiative was to reduce the potential for inappropriate use of expensive
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long acting opioids. The initiative was able to reduce the number of prescriptions of
expensive long acting and potentially inappropriate opioids from 165 to 69 prescriptions
in less than 6 months (from November 2007 through March 2008). Projected annual
savings to the facility from the initiative was reported at $276,998. Although not
specifically measured, there was a general consensus that the initiative improved overall
patient safety due to healthcare providers’ increased knowledge on the safe use of opioids
and increased awareness of patient safety issues related to the use of methadone, another
long acting opioid (Kharlamb, n.d.).
In Northern California VA, a working group developed a program to minimize
opioid diversion and to align opioid use within their VA according to their Pain
Management Guideline. The results of their work have not been published but the goals
of the initiative were fourfold: (1) Better manage chronic pain based on World Health
Organization’s Pain Ladder, (2) Decrease number of short-acting opioids prescribed, (3)
Create continuity in pain management amongst VA clinicians, and (4) Minimize
diversion (Lockhart, 2008).
The American College of Preventative Medicine and the American College of
Physicians are among several professional organizations that have released formal
position statements regarding the growing problems with prescription opioid abuse and
the need for patient monitoring to help identify abuse and misuse of opioids (American
College of Preventative Medicine, 2011; Kirschner, Ginsburg, & Sulmasy, 2013). The
American Association of Nurse Practitioners website has a link in their clinical resource
menu where interested practitioners would be redirected to the National Institute of Drug
Abuse website for clinical information about prescription opioid abuse and mitigation
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strategies including regular monitoring through urine drug screens, use of prescription
drug monitoring databases, and pill counts (American Association of Nurse Practitioners,
n.d.; National Institute of Drug Abuse, n.d.).
Based on this literature review, there is a dire need for an intervention that could
address the worsening problem of opioid abuse and misuse in the United States and the
Department of Veterans Affairs. A common theme among currently available clinical
practice guidelines such as from the VA/DoD, American Pain Society, and American
Academy of Pain Medicine recommend regular monitoring of patients on chronic opioid
therapy to help identify abuse as early as possible and refer these patients for treatment.
Patients with certain risk factors for abuse and misuse of opioids are at greater risk for
opioid related complications and thus would need more intensive monitoring. The OMC
was developed and implemented to address this specific need to intensively monitor high
risk patients on chronic opioid therapy.
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CHAPTER 3
THEORETICAL UNDERPINNING OF THE PROJECT
Kurt Lewin’s Change Theory was selected as the conceptual framework for this
project. The theoretical framework provided the structure and guidance needed to
analyze the process of change to implement the OMC. The theoretical framework
identified the forces that drive the change forward and addressed the barriers that resist
the change. The project involved the implementation of OMC in VA-Las Vegas as a
resource clinic where PCPs could refer patients who were at high risk for opioid abuse
and/or misuse. The operational framework embedded within Lewin’s Change Theory is
the Force Field Analysis Model. This model was used to assess individual and group
behavior that can progress or impede change and evaluate organizational readiness for
change (Baldonado et al., 2011). Two dynamic and opposing forces that impact change
are: driving forces – those that initiate and encourage the change to occur and restraining
forces – those that prevent the change from occurring (Baulcomb, 2003). For change to
transpire successfully, the driving forces must outweigh the restraining forces.
Lewin’s Change Theory identifies three phases to the change process: unfreezing,
changing, and refreezing (Maxwell, 2009). Unfreezing requires communication of the
need for change. Changing involves implementation of new behaviors and practices.
Refreezing occurs when the change has been integrated into practice (Borkowski, 2009).
Achievement and sustainment of this practice change renders Lewin’s Change Theory the
ideal framework for guidance in this OMC.
A change in the long-held belief that chronic opioid therapy as a safe and
effective treatment for chronic pain was the greatest positive factor for the development
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of the OMC. Current literature and educational offerings like continued medical
educations are being bombarded with data that exposes the current problem of chronic
opioid therapy. Additionally, professional organizations such as the American College of
Preventative Physicians, American College of Physicians, American Pain Society,
American Academy of Pain Medicine, and the Federation of State Medical Boards have
all released formal position statements regarding the growing problem of prescription
opioid abuse and the need to monitor patients to help identify abuse and misuse of
prescription opioids (American College of Preventative Medicine, 2011; Chou et al.,
2009; Federation of State Medical Boards, 2013; Kirschner et al., 2013). In 2011, the
Institute of Medicine (IOM) released its report titled, “Relieving Pain in America: A
Blueprint for Transforming Prevention, Care, Education, and Research” (IOM, 2011).
In its report, the IOM noted a very serious growing problem in the United States of
opioid abuse and misuse. Current shortage in PCPs combined with increasing number of
patients entering the VA system for medical care is causing access problem to patients
and staff dissatisfaction among PCPs who have to manage increased number of patients
and more complicated patients. Among the complicated and challenging patients seen in
primary care are patients on chronic opioid therapy with history of substance abuse who
must be monitored carefully for judicious use of opioids. These patients are often seen
more frequently than patients not on opioid therapy because of regulatory mandates in
opioid therapy. This problem was clearly demonstrated during the needs assessment
survey done for this OMC project whereby 100% of PCPs who participated in the survey
voiced their support for the development of the OMC to assist them in the management
of patients on opioid therapy. The growing problem with opioid abuse and misuse was a
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call for concern that many clinicians including leadership were aware. Using Lewin’s
Change Theory, the first phase was initiated by communicating with stakeholders, mainly
the chief of primary care and PCPs, of a need to develop a specialized referral service
that can assist PCPs in managing their patients with risk factors for abuse and misuse of
opioids.
The driving forces for change exceeded whatever restraining forces that may be
encountered in the development of OMC. The support from stakeholders, such as those
from PCPs, and the leadership (Chief of Primary Care) were major driving forces to
support the implementation of change through the development of OMC (See Appendix
B for the copy of letter of support from Chief of Primary Care). Among the restraining
forces that would be expected in the successful implementation of OMC are those that
were likely to occur from patients who were referred by their PCPs into the OMC.
Patients who currently abuse or misuse their opioids but have not been identified yet by
their PCPs were subjected to intensive opioid monitoring that exposed their aberrant
behaviors and likely resulted in patient dissatisfaction. In these patients, once they were
determined to meet the definition of major aberrant behavior (positive UDS for nonprescribed opioids and/or positive UDS for stimulants like cocaine and
methamphetamines), they were referred to the ADTP of the VA-Las Vegas to help them
with their problem.
In the movement phase, during the development of the OMC, multiple formative
evaluations of the operation of the clinic were strategically designed to ensure that
problems and positive experiences in the early implementation of the OMC were noted
and corrected if needed. A series of staff and provider educations were implemented and
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included in the OMC development plan to ensure continued communication between
PCPs and the OMC. Educational offerings provided during the development of the OMC
also served another purpose besides garnering feedback and support from stakeholders.
The educational offerings also provided the essential information to the PCPs of the
problem of opioid abuse and misuse among patients. The offerings helped enhance
exposure of PCPs to the problem and helped aligned them to the recommendations from
the VA/DoD clinical practice guideline.
In the refreezing phase, summative evaluation of the OMC was conducted to
report findings to leadership as well as PCPs for continued operation of the OMC. The
positive findings from evaluating the OMC were very encouraging and support the
effectiveness of the OMC in identifying misusers and abusers of opioids. The evaluation
also showed improved PCP compliance with the recommendations from the VA/DoD
clinical practice guideline. The long-term effect of the OMC in increasing provider
satisfaction, and in increasing overall patient satisfaction will be evaluated after a year of
OMC operation.
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CHAPTER 4
PROJECT PLAN
Needs Assessment
A needs assessment was done on January 24, 2013. An online survey using
SurveyMonkey was sent to all PCPs in the VA-Las Vegas. At the time the survey was
sent, there were forty PCPs in the VA-Las Vegas facility. The response rate for the
survey was 80% (32/40). All PCPs who responded to the survey indicated the need for
an OMC to assist them in the management of patients on chronic opioid therapy (Figure
2). Of those who responded, 62% reported that they have knowledge of the VA/DoD
clinical practice guideline on opioid therapy but less than 60% indicated they follow the
clinical practice guideline (Figure 3; Figure 4). Additionally, 80% of the PCPs who
responded in the survey indicated that they routinely monitor their patients on chronic
opioid therapy (Figure 5).

Figure 2. Percentage of PCPs interested in the Opioid Monitoring Clinic.
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Figure 3. PCPs’ knowledge of the VA/DoD opioid use clinical practice guideline.

Figure 4. Percentage of PCPs who follow the VA/DoD clinical practice guideline
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Figure 5. Percentage of PCPs who regularly monitor their patients using
urine drug screens.

In addition to the needs assessment survey, data from a VA Las Vegas facility
was obtained to quantify the number of patients on chronic opioid therapy. In March
2013, there were 5,881 patients on opioid therapy (Figure 6). Of these, there were 738
patients on at least 120mg of morphine equivalent dose (MED) per day and 333 patients
were on at least 200mg MED per day. At least 13% of patients on opioid therapy in VA
Las Vegas were on high dose of opioids (>100mg MED/day). Previous published studies
reported that the incidence rate of patients on chronic opioid therapy for chronic
noncancer pain who abuse their prescription opioid is about 30% (Reid et al., 2002; Von
Korff et al., 2011). The five year prevalence rate of opioid abuse among veterans is at
least 3% (Baser et al., 2013). Based on these baseline data, there may be around 1,800
veterans who are likely abusing and misusing their opioids. The need to prevent abuse
and misuse of opioids is clearly indicated in VA Las Vegas. In effect, the OMC is
specifically designed to identify abuse and misuse of opioids through evidence-based
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mitigation strategies that would help identify patients who abuse and misuse their
prescription opioids.

Location
Las
Vegas

Patients
(n)Daily
Morphine
>120mg

Patients
(n) Daily
Morphine
>200mg

All
Patients
with
Opioid Rx
(n)

738

333

5,881

%Patients
with
Morphine
>120mg

%
Patients
with
Morphine
>200mg

13%

6%

Figure 6. VA Las Vegas data on the number of patients on opioid therapy.

Population Identification
The VA Las Vegas is a catchment area for the 240,000 veterans living in
Southern Nevada. Approximately 60,000 veterans are enrolled in the VA Las Vegas.
About 10% of veterans eligible to be seen in the VA Las Vegas are women. The OMC
receives referrals from all Primary Care Clinics of the VA-Las Vegas including referrals
from specialists of the VA Las Vegas Integrated Pain Clinic. The Primary Care Clinics
see veterans with ages ranging from 18 years old and over.
Patients admitted to the OMC are veterans with chronic pain and on chronic
opioid therapy. Additionally, they have certain risk factors that put them at high risk for
abuse or misuse of opioids. These factors include documented aberrant behaviors such as
multiple early refill requests, history of lost medications, negative drug screens, positive
drug screens for substance not prescribed, and noncompliance with plan of care. History
of substance abuse including alcohol, cocaine, heroin, and marijuana are also known risk
factors for opioid abuse and misuse of opioids (Krebs et al., 2011; Meghani et al., 2009).

22

OMC patients were eligible for inclusion in an OMC Study aimed at evaluating
OMC effectiveness if the patients gave their informed consent. Eligibility for study
participants seen and evaluated in the OMC included age 18-65 with provider-diagnosed
chronic noncancer pain and on chronic opioid therapy. Study participants also needed to
have a history of substance abuse (i.e. heroin, cocaine, alcohol), and/or provideridentified and documented aberrant behaviors (i.e. report of medication loss, request for
early refills) (See Appendix C for OMC protocol and eligibility requirements).
For provider participants on this study, the eligibility criteria included physicians,
physician assistants, and advanced practice nurse practitioners working for the VA Las
Vegas Primary Care on a full time and part time basis with ages ranging from 25-80.
Forty-two PCPs were eligible to participate in the study when the online survey was sent
to all PCPs in VA Las Vegas on February 18, 2014.
Identification of the Project Sponsor and Key Stakeholders
The development and implementation of the OMC as a referral service within the
Primary Care service in the VA Las Vegas has strong support from the PCPs and
leadership. The growing problem of opioid abuse among patients is a constant concern
for clinicians as well as administrative leadership. The problem not only affects patients
but it also has far reaching effects to clinicians who prescribe opioids, the pharmacy
service that dispenses the opioids, and the organization that is burdened with the high
economic cost of opioid abuse and misuse. The general public is likewise affected.
Patients who divert their opioids by selling them or by sharing them with friends and
families are at risk for opioid-related complications including death by using these
diverted opioids for nonmedical reasons (CDC, 2011, November 1). The strong support
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from key leadership, mainly the of Chief of Primary Care, was further strengthened by
the findings from the needs assessment survey which revealed an overwhelming interest
by PCPs in VA Las Vegas for a clinic that would assist them in the management of high
risk patients on chronic opioid therapy. Furthermore, the growing concern of an
epidemic problem of prescription opioid abuse in many cities including Las Vegas and
nationwide is also a main motivation for the development and continued support in the
development and the implementation of the OMC.
Organizational Assessment
The major components of the VA health system structure are Primary Care
Service, the Mental Health Service, Medicine Service, and Nursing Service. The OMC is
administratively accountable to the Primary Care Service with close collaboration with
the Mental Health Service and Medicine Service. There are currently six Primary Care
Clinics in the VA-Las Vegas system (four in Las Vegas, one in Pahrump, and one in
Laughlin, Nevada). The OMC is administratively assigned to the Primary Care Service
under the supervision of the Chief of Primary Care. The Primary Care Service was
responsible for clinic profile development, OMC clinic staffing, and OMC logistical
support including allocation of clinic rooms, and patient examination equipments. Each
Primary Care Clinic has their own mental health clinic staffed by mental health clinicians
including psychiatrists, psychologists, mental health nurse practitioners, substance abuse
counselors, and mental health nurses.
The Mental Health Service – alcohol and drug treatment program (ADTP) of the
VA-Las Vegas is administratively run by the Mental Health Care Line. The ADTP is
utilized for patients found to be abusing and/or misusing their opioid medications. The
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Medicine Service is where the Integrated Pain Clinic belongs. The VA-Las Vegas has an
Integrated Pain Clinic located in the main hospital of the VA-Las Vegas. The Integrated
Pain Clinic is administratively run by the Medicine Service. The clinic is staffed by
physicians and physician assistants who specialize in pain management. The following
services are offered in the integrated pain clinic: (a) chronic pain management, (b)
acupuncture, (c) chiropractic services, (d) anesthesia injections, (e) physiatry and
rehabilitation medicine, and (f) osteopathic manipulation therapy. Patients with MED of
>200mg per day of opioid therapy were referred to the Integrated Pain Clinic per OMC
clinic protocol for further pain evaluation and management. In addition to referring
patients on very high MED, the OMC also referred patients to the Integrated Pain Clinic
when there was a discovery of abuse and misuse of prescription opioids. Patients who
were found to be abusing their prescription opioids were referred to the ADTP and
sometimes to the Integrated Pain Clinic for management of their pain symptoms through
non-opioid therapy using one or more of the services that the Integrated Pain Clinic
provides. Patients referred to the Integrated Pain Clinic due to abuse and misuse of
opioids were eventually discharged from the OMC but may be referred back in the future
by the Integrated Pain Clinic clinicians or by their PCPs according to the OMC eligibility
criteria. Lastly, OMC referred patients to the Integrated Pain Clinic when there was no
history of using non-pharmaceutical modality in the management of pain symptoms in
veterans referred and seen in the OMC.
The OMC is supported by the other clinical services including the Pharmacy
Service, Laboratory Service, Nursing Service, and Health Administration Service (HAS).
The pharmacy service is located in the same building as the OMC and stocks most of the
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prescribed medications in Primary Care including controlled substances,
antihypertensive, hypoglycemic, cholesterol lowering drugs, antibiotics, and others.
Although some patients can choose outside pharmacy to dispense their medications, all
controlled substances including opioids are only dispensed in the VA-Las Vegas. The
Pharmacy Service provided the baseline and subsequent evaluation reports of opioid use
in the VA Las Vegas including number of total opioid use with breakdown to specific
type of opioids and its associated pharmacy cost. The Laboratory Service provided the
testing of urine drug screens for patients admitted in the OMC. Confirmatory tests using
gas chromatography and mass spectrometry (GC/MS) are done by the laboratory service.
The nursing service provided the nursing staff for the OMC. The HAS provided the
Medical Support Assistant (MSA) staff that assisted in scheduling patients and performed
other front desk administrative duties.
The OMC is an APRN-led clinic. The APRN is responsible in the development,
implementation and sustenance of the OMC in collaboration with other specialty clinics
within the VA-Las Vegas, and in consultation with the Chief of Primary Care. The OMC
is headed by an APRN and assisted by a team of a Registered Nurse (RN), Licensed
Practical Nurse (LPN), and MSA. This teamlet came from the Primary Care team in the
Southwest Primary Care Clinic (SW PCC) and worked full time (Monday through
Friday) from 0800-1700. The teamlet operates in the same rooms where the team works
full time on other times not related to the OMC. The rooms are dedicated to the teamlet
so the use of the rooms is exclusive for primary care visits or for OMC visits. The APRN
has two patient rooms to see patients and alternated rooms with an RN/LPN for intake of
patient information.
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Team Selection and Formation
The OMC was conceptualized by an APRN who worked ten years in the primary
care management of veterans including homeless veterans. This APRN is also the VA
Las Vegas Primary Care Champion in Pain Management. A Primary Care Champion in
Pain Management is a clinician who has been identified by organization leadership to be
a clinician with competence and skills to be a resource in Primary Care pain management
for other clinicians in the facilities. Each facility in the VA has at least one Primary Care
Champion; the VA Las Vegas has one Primary Care Champion. All Primary Care Pain
Champions were sent by the VA for advanced training in evidenced-based pain chronic
pain management. The Pain Champion collaborates closely with the Integrated Pain
Clinics in the VA and are members of the local and network Pain Management
committees in the VA. The APRN was the team leader for the development and
implementation of the OMC.
Once commitment by the Chief of Primary Care was secured to support the
development and implementation of the OMC by the APRN, team selection was
identified as the next phase. OMC staff were diverted from the current Southwest
Primary Care Clinic teamlet led by the APRN.
The OMC development team was also supported by the Information Technology
Department in the development of clinical templates that needed to be integrated in the
electronic medical record of the VA Las Vegas. A clinical application coordinator
(CAC) provided the expertise in the integration of the electronic templates including the
electronic consults and progress notes that were associated in the operation of the OMC.
The CAC assisted in the development of a test clinic in the test account of the VA CPRS
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for OMC staff to practice, modify and improve. OMC staff practiced with consult
management and documentation in the OMC clinic using the test clinic. Consult
management practice involved using a practice patient to refer a patient to the OMC to
ensure receipt of the electronic consult in the practice environment of CPRS. Once the
electronic consult was ordered, the OMC staff practiced with the consult by leaving
comments in the electronic consult to ensure receipt of additional comments by all OMC
and the referring provider. A trial of patient scheduling was also done during the practice
session. Lastly, test OMC clinical notes were attached to the consult to ensure that all
personnel associated with the consult were being alerted of any activities associated with
the electronic consult. Among the activities tested during the testing phase of the
electronic consult included consult receipt, consult discontinuation when an OMC was
not an appropriate consult for the OMC, consult transfer when a consult was incorrectly
sent to the OMC but was intended for other specialty consult, patient scheduling,
attachment of notes, and OMC staff comment addition. Once members of the OMC staff
were satisfied with the OMC electronic consult management including documentation,
the test account was activated into the live account for live implementation of the OMC
in VA Las Vegas. Immediately after the OMC consult service was placed into the live
account, PCPs interested in referring patients to the OMC were able to refer patients to
the OMC using the electronic consult option in CPRS.
Define the Scope of the Project
The operation of the OMC is dedicated to the management of patients on chronic
opioid therapy. First, it is expected that the OMC has the potential to improve overall
patient satisfaction in the long term since patients admitted in the OMC had their opioids
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renewed timely and had their opioid therapy aligned with the VA/DoD clinical practice
guideline. Timely renewal of opioids can result in a decrease in unscheduled clinic visits
and/or off-hour visits to local emergency departments (Wiedemer et al., 2007). Further,
the potential for opioid-related complications can be reduced as opioid therapy is geared
toward current guideline recommendations in the management of chronic pain using
chronic opioid therapy. By reducing the pill burden associated with using short acting
opioids (these opioids tend to be taken at least four times daily in order to achieve a
continuous analgesic effect), the change to long acting opioids based on the VA/DoD
clinical practice guideline has the potential to significantly reduce the number of pills
dispensed to patients each month. For example, hydrocodone/acetaminophen is usually
written to be taken one to two tablets every four to six hours during the day resulting to at
least 180 tablets of this prescription opioid being dispensed to a patient every single
month. In contrast, morphine sulfate sustained acting tablets can be given to a patient
with the same MED as the hydrocodone but with fewer pills per month. The morphine
sustained acting pills can be taken twice daily and would reduce the number of pills per
month being dispensed to a patient with high risk factors for opioid abuse and misuse
from 180 pills to 60 pills per month.
Second, the scope of change within the VA Las Vegas can be a “win-win”
scenario to everyone involved. The OMC can decrease the workload from the Integrated
Pain Clinic since some patients who would otherwise be referred to their service were
referred to the OMC. The VA Las Vegas facility would benefit from expected pharmacy
cost savings and reduced utilization of outside services (i.e., ED visits), and expected
improvement in patient access to PCPs since patients admitted to the OMC would allow
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openings for other patients seeking appointments with their PCPs. Lastly, the VA Las
Vegas also would benefit from the expected increased PCP and patient satisfaction.
Third, the public would benefit from the OMC as potentially dangerous
prescription opioids being diverted into the community via sale or sharing can be reduced
or stopped through the OMC’s process of identifying patients who abuse and misuse
opioids.
In summary, the creation and implementation of the OMC can effectively assist
PCPs in the management of high risk patients on chronic opioid therapy for chronic
noncancer pain. PCPs would be able to refer eligible patients to the OMC based on
specific eligibility criteria. In return, the OMC has the potential to improve the quality of
patient care by aligning the use of opioids in the management of chronic noncancer pain
with VA/DoD current evidence-based guideline. The implementation of the OMC also
has the potential to be an effective strategy to reduce the cost of healthcare delivery to
patients by reducing the number of unnecessary opioids pills dispensed by the VA-Las
Vegas, and by potentially preventing opioid-related complications by discontinuing
opioid therapy on patients who are found to be abusing and misusing their prescription
opioids. Lastly, the OMC has the potential to improve PCP satisfaction by off-loading
some of their time in the management of complicated high risk patients on chronic opioid
therapy.
Setting
The OMC was piloted in the SW PCC of Southern Nevada Healthcare System
Las Vegas under the Primary Care Line and staffed by a teamlet that belonged to the
Primary Care Line. Arrangements were made with the Chief of Primary Care, laboratory
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service, pharmacy service, ADTP staff, nursing service, and HAS in the development and
implementation of the OMC. The Chief of Primary Care has approved the development
of the OMC and supported the implementation of OMC within the Primary Care line to
assist PCPs in the management of high risk patients on chronic opioid therapy for chronic
noncancer pain.
Population of Interest
Veterans who were enrolled in the VA Las Vegas, assigned to a primary care
provider, and had risk factors for abuse and misuse of opioids were the target population
for the OMC development and the study to evaluate the OMC. These veterans were on
chronic opioid therapy for chronic noncancer pain. Veterans with history of substance
abuse such as history of cocaine, heroin, alcohol abuse, and marijuana use can be referred
to the OMC by their primary care providers. Veterans with documented aberrant
behaviors such as frequent requests for early refills due to loss of opioid medications
and/or due to running out early were also eligible to be referred to the OMC. Veterans
who consistently test negative for their prescribed opioids despite regularly refilling their
opioids with documentation that they were indeed taking their opioids were also eligible
to be referred to the OMC for regular monitoring.
Measures and Instruments
The OMC used the following tools to manage patients evaluated and admitted in
the clinic. At admission, a basic demographic data were documented in the initial clinical
note template which is an electronic documentation system that healthcare providers
working for the VA utilize to document each patient visit. The initial OMC clinical note
template included gender, age, main source of pain, history of substance abuse (i.e.
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opioid, alcohol, cocaine, heroin, marijuana, and/or other history of substance abuse such
as methamphetamines, barbiturates and benzodiazepines (See Appendix D for the OMC
clinic note).
Patients were screened for suicidal or homicidal thoughts. At each visit, patients
were asked if they had suicidal or homicidal thoughts in the last 30 days. Further,
patients were also asked if they had a history of suicidal attempt in the past. Based on
patient responses to these questions, patients were categorized into four categories of risk
threats: (1) no risk (2) low risk (3) moderate risk and (4) high risk. Anyone who was
found to be suicidal or homicidal or who were placed on moderate risk or high risk
categories were excluded from OMC and instead referred to appropriate specialty care for
further evaluation. The No risk category included those patients who did not have any
suicidal thoughts in the last 30 days and no suicidal attempts in their history. The low
risk category included those patients who had no suicidal thoughts or homicidal thoughts
in the last 30 days but had distant history of suicidal attempts in the past. The mode of
suicidal attempt in the past was documented in the OMC clinical note. The OMC staff
also had the discretion to screen patients further when indicated using various screening
tools integrated in the VA CPRS such as the PHQ-2 and PHQ-9 as depression measures.
The OMC staff also had the discretion not to admit patients into the OMC and refer
patients to the Mental Health Care service when the OMC staff based on their
professional opinion and evaluation that patients would not be a candidate for the OMC
due to unstable or untreated mental health conditions. Next, vital signs were obtained
which included blood pressure, heart rate, respiratory rate, height, weight, temperature,
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and current pain intensity (0-10 with zero as having no pain and 10 as having the worst
pain they could imagine).
The OMC utilized intensive monitoring for opioid abuse/misuse through urine
drug screens, pill counts, and controlled substance drug utilization review. The
controlled substance drug utilization review was done by reviewing the Nevada
Prescription Monitoring Program (PDMP) database which is a database of patients in
Nevada who received schedule II-IV controlled substances. For veterans with addresses
in or near Arizona, the Arizona Controlled Substance Prescription Monitoring Program
(CSPMP) was also accessed. For addresses in or near Utah, a PDMP report was
requested via a fax request to Utah’s PDMP office as Utah only allows access to their
PDMP database to clinicians licensed in their state. The PDMP databases are operated
by each respective state to allow healthcare providers who were given access to the
database to inquire about controlled substance use of a patient based on certain
identifying information such as name and date of birth. Information that can be found in
these databases includes the name, dosage, and amount of opioid pills dispensed, the
healthcare provider who wrote the prescription, the pharmacy that dispensed the opioid
prescription and the date the opioid prescription was dispensed to the patient. Accessing
the state prescription monitoring program database in addition to accessing the VA
medical record can be helpful in identifying aberrant behaviors such as “doctor shopping”
among patients who misuse their opioid prescriptions.
Urine drug screens were done at the conclusion of the initial visit with the OMC,
and repeated at the discretion of the OMC staff. Patients were asked to complete the
Brief Pain Inventory (BPI) short form and the results were documented in CPRS. A pain
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Screening Tool by Alturi and Sudarshan (2004) was also completed and documented in
CPRS at the initial visit.
Lastly, an online provider satisfaction survey was developed through
SurveyMonkey and sent to all PCPs in the VA Las Vegas on February 18, 2014 to assess
the satisfaction of PCPs who referred patients to the OMC (See Appendix E for a copy of
the Provider Satisfaction Survey). Additionally, the provider satisfaction survey included
questions related to PCP compliance with the VA/DoD clinical practice guideline.
Brief Pain Inventory. The short form of the BPI was used at admission and in
every subsequent clinic visit to assess for trend in pain intensity and functional status
(See Appendix F). The BPI is a self administered pain assessment that has been widely
used in documenting pain intensity and how pain interferes with function among patients
with chronic noncancer pain. The BPI measures sensory pain intensity and the functional
intensity or the degree that pain interferes with different areas of life (Cleeland & Ryan,
1994). The validity of BPI is well reported in the literature (Keller et al., 2004; Mendoza,
Mayne, Rublee, & Cleeland, 2006). Permission to use the BPI instrument was obtained
from the developer (See Appendix G).
Pain Screening Tool. Additionally, each patient evaluated in the OMC for
admission in the clinic had the pain Screening Tool developed by Atluri and Sudarshan
(2004) completed by the OMC clinician to assess their risk for inappropriate use of
opioids (See Appendix H). In their validity study, patients who scored more than 3
points on the 6 item questionnaire (1 point each for each item) were noted to have a 17
fold increased risk of opioid abuse/misuse than those who scored less than 3 points.
When used in combination with other risk reduction strategies, the likelihood of
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identifying patients who abuse or misuse opioids can be dramatically improved.
Permission to use the Screening Tool was obtained from the instrument developer for use
in this project and study (See Appendix I).
Timeline
As part of a continuous quality improvement (CQI) initiative for the VA-Las
Vegas, the OMC was developed and implemented. The OMC started screening patients
in July 2013. An OMC Study aimed to evaluate the clinic commenced immediately after
approval from the University of Nevada Las Vegas (UNLV) Institutional Review Board
(IRB) on November 22, 2013 through an expedited review approval process (See
Appendix J for the copy of the UNLV IRB approval). Patients who were previously seen
in the OMC and eligible to be participants for the OMC study were asked to participate in
the study through voluntary informed consenting process. New referrals to the OMC
after the IRB approval were asked to participate in the OMC study if they met the
eligibility criteria for the OMC study. Data for the OMC study were collected from July
1, 2013 through February 23, 2014 for those patients who elected to participate in the
OMC study.
In addition, the provider satisfaction and OMC evaluation online survey was sent
via secure email to all PCPs on February 18, 2014 and data from these surveys were
collected for analysis on February 28, 2014. Findings from the three and six months
OMC evaluation were reported to leadership for continued operation and/or possible
expansion of program (See Appendix K for the project timeline).
Project Objectives and Activities
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Objective 1. Developing an OMC within the Primary Care Service allowed PCPs
to refer patients who meet the eligibility criteria. Once the OMC was developed,
implemented, and activated, the OMC took over the management of chronic opioid
therapy including opioid renewal, opioid dose adjustment, opioid substitution (from short
acting to long acting using an established online opioid morphine equivalence calculator
[GlobalRPH] developed by McAuley (2013, April 18), monitoring for misuse/abuse of
opioids, and regular clinic visits for pain management based on the 2010 VA/DoD
clinical practice guideline. The guideline recommends the use of long acting opioids
instead of short acting opioids in the management of chronic pain using chronic opioid
therapy and the use of regular and random screening using urine drug screens and the
PDMP (Department of Veterans Affairs and Department of Defense, 2010). The
following tasks were completed to develop the OMC within the VA Las Vegas:
(1) Members of the OMC staff were diverted from the current Southwest Primary
Care Clinic teamlet lead by the APRN. The teamlet consisted of the lead APRN, RN,
LPN, and a MSA. The teamlet assumed the OMC operation on daily clinic basis
(Monday through Friday from 0800-1400).
(2) An electronic clinic referral template was developed to allow PCPs to refer
patients to the OMC electronically using the VA’s CPRS. The electronic referral
template allowed communication between the OMC and PCPs electronically every time a
clinic note associated with the referral was documented and electronically signed in the
CPRS. The OMC also developed PCP in-service informational sessions regarding the
OMC and the VA/DoD Clinical Practice Guideline for the management of chronic pain
using opioids and were presented to the PCPs in their monthly staff meeting in June
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2013. Three additional clinician in-services were developed by the OMC staff and were
presented to VA Las Vegas APRNs in their Quarterly Meeting in October 2013, VA Las
Vegas Primary Care Nursing staff in their monthly meeting in November 2013, and to the
Southwest Primary Care Clinic’s Primary Care Providers in their monthly meeting in
December 2013. All presentations were done using PowerPoint.
Another PowerPoint presentation to all clinicians in the VA Las Vegas was
presented on March 18, 2014 during the monthly Grand Rounds to update clinicians in
the encouraging the trend of decreased use of opioids in the facility, the use of long
acting opioids, the increased use of urine drug screens to monitor patients on opioids, and
the increased use of the Prescription Drug Monitoring Program state database to monitor
potential “doctor shopping” (obtaining opioids from multiple healthcare providers).
These presentations also allowed for interaction between the OMC staff and PCPs with
questions addressed.
(3)The laboratory protocol was developed and finalized to allow for urine drug
screening and for positive results to be automatically sent for confirmation for certain
substances like amphetamines due to high false positive results of this substance in the
urine drug screen.
(4)An application for access to the Nevada’s Prescription Monitoring Program
and Arizona’s Controlled Substances Prescription Monitoring Program were filed and
completed allowing OMC staff access to these databases.
(5) The lead APRN developed a training program for the staff of the OMC prior
to OMC activation. The purpose of the training was to orient staff with the goals of the
OMC and the protocols of the OMC including the tasks for each respective discipline.
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(6) An OMC clinic profile was developed in collaboration with the Chief of
Primary Care which was activated prior to the OMC implementation. The clinic profile
facilitated scheduling of patients to the OMC on specific OMC clinic days and time
periods to allow for adequate time for blocking primary care clinic visits of the teamlet
that would be allocated to the OMC schedule.
Objective 2. The activation and implementation of the OMC took place once the
OMC was developed and prepared for activation. The OMC accepted patients to be
admitted to the OMC if they were found to be eligible to be admitted to OMC. The
eligibility criteria included all of the following: (a) Pain of more than three months in
duration, morphine equivalent dose of 100mg per day, and documented evidence of
aberrant behaviors including early requests for opioid refills, report of loss of opioid
medications, multiple emergency room visits for pain while on opioid therapy, noncompliance with drug monitoring such as urine drug screen (orders for drug screen not
being done by patient), negative urine drug screen for prescribed opioids, or (b) history of
substance abuse including heroin, cocaine, alcohol and marijuana, or (c) morphine
equivalent dose of 0-100mg per day but exhibiting aberrant behaviors.
Any eligible veteran with high risk for opioid abuse or misuse can be referred by
their PCPs to the OMC. A notification within the electronic consultation was done to
identify referred patients admitted to the OMC. For patients who were accepted to the
OMC, the MSA or the nursing staff scheduled an initial clinic appointment in one of the
time slots specific for OMC clinic scheduling. The OMC staff provided call back
confirmation of the appointment 1-3 days prior to the appointment date to decrease the
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risk of no-shows and rescheduled an appointment if the appointment time was no longer
feasible to the patient.
At the initial OMC clinic appointment, patients were given information about the
OMC and the reason they were referred to the OMC. Eligible patients for the OMC
study were then given an explanation of the study and were asked to sign the Informed
Consent for voluntary participation in the study (See Appendix L for a copy of the
Informed Consent). A copy of the signed informed consent was given to each patient for
their review and record keeping. The original signed informed consent was kept and
secured in the clinic for record keeping and for accounting on the number of participants
in the study. Eligible patients who elected not to participate in the study were given an
explanation that declining to participate would have no difference in the care they receive
from the OMC compared to patients who elected to participate in the study.
Patients were then asked to complete the BPI short form and sign an Opioid Pain
Agreement, if not already completed previously. The Opioid Pain Agreement served two
purposes. First, the content in the agreement provided patient education information
regarding the potential hazards of opioid use. Second, the content provides specific
expectations from the patient if opioid therapy is to be initiated. For example, the
agreement contained instruction for the patient that there should only be one healthcare
provider prescribing opioids to the patient and that a patient should inform other
healthcare providers who may potentially prescribe them opioids that they were currently
getting opioids from the VA-Las Vegas. Further, patients were informed in the
agreement that failure to comply with recommendations for chronic opioids therapy
could result in appropriate discontinuation of opioid use in the management of their
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chronic pain. Lastly, the agreement also contained statements that patients on opioid
therapy agree to submit to random drug screens, abide with random pill counts, and
comply with other risk reduction strategies recommended by the opioid prescribing
healthcare provider. The Opioid Pain Agreement was signed electronically and became
integrated in the patient’s medical record once signed by both the patient and the opioid
prescribing healthcare provider. A copy of the signed agreement was given to the patient
for reference.
Vital signs were obtained which included blood pressure, heart rate, respiratory
rate, height, weight, temperature, and current pain intensity (0-10 with zero as having no
pain and 10 as having the worst pain they could imagine). After the intake with nursing
staff (this can be done by the LPN or RN), patients were then seen individually by the
APRN for review of history, suicidal/homicidal risk assessment, physical exam, and
management of their pain as it related to opioid therapy. A pain Screening Tool by Alturi
and Sudarshan (2004) was completed by the APRN clinician at admission and
documented in the electronic record. All documentations were done in the CPRS.
Every initial OMC clinical note included the following information that were
documented electronically via CPRS: (a) reason for referral to OMC, (b) history of
substance abuse, (c) relevant diagnosis for opioid therapy, (d) pain history,
(e)suicidal/homicidal risk assessment, (f) BPI, (g)adverse drug reaction or side effects,
(h)aberrant behaviors, (i) current opioid therapy including last dose taken (j) morphine
equivalent dose of current opioid therapy (k) last urine drug screen date and results (l)
PDMP report and findings (m) vital signs, (n) physical exam findings, (o) Screening
Tool, and (p) plan of care including opioid therapy continuation, dose adjustment, opioid
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substitution (from short acting to long acting), or opioid discontinuation; opioid
misuse/abuse monitoring, referral to other pain modality clinics or ADTP; and return
visit.
After each clinic visit, patients were evaluated for the need to submit a random
urine drug screen according to the OMC protocol. If a urine drug screen was recently
done (less than 30 days) prior to the OMC visit, the OMC staff had the discretion if a
repeat testing was necessary. If no recent urine drug screen on record can be found in the
CPRS, patients seen initially in the OMC were asked to submit a urine specimen to the
laboratory for screening. They were given a laboratory number and were instructed to
submit a urine sample to the laboratory located in the same building as the OMC. The
OMC staff verified submission of urine sample by patients through the CPRS which
showed active status for the ordered laboratory test. Once the laboratory results were
back, the results were documented in the CPRS OMC clinic note with annotation of
change in the plan of care as needed. Patients noted to have a positive urine drug screen
for illicit substance such as cocaine, heroin, methamphetamines, barbiturates, and
marijuana (without documentation of receipt of Nevada legal marijuana program) were
informed of the unexpected findings in their urine drug screen and were recommended
for referral to the ADTP of the VA-Las Vegas.
A PDMP database inquiry to the state database on controlled substance use was
done on each patient on the initial visit and was repeated as needed when there was
suspicion for obtaining multiple opioid prescriptions from other healthcare providers.
After each clinical visit, patients who were recommended to continue on opioid therapy
had their new prescription of opioid ordered electronically. These patients were also
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given an appointment for follow up at the recommended time frame which could be
monthly but was decided by OMC staff depending on the patient’s case. Follow up
appointments ranged from every week to every three months. Patients with
recommended face to face follow up of more than a month had their PDMP record pulled
every time patients requested timely refill of their opioids. Patients noted to have
positive PDMP findings of ‘doctor shopping” were informed of the unexpected findings
and were recommended for referral to the ADTP or the MHC of the VA-Las Vegas. A
notification was also sent to the Behavioral Abuse Committee of the VA Las Vegas for
consideration in adding an electronic flag in CPRS that would alert any clinicians who
open the patient’s record to not provide any opioids due to documented history of “doctor
shopping”. The Behavioral Abuse Committee meets on a monthly basis and receives
notifications from clinicians regarding behavioral issues related to their patients that
warrant notification of all clinicians to ensure communication among all clinicians
regarding serious patient behaviors.
After each OMC clinic note was signed by the OMC clinician, the referring PCP
was automatically notified of the action of the OMC on their referred patients.
Additionally, PCPs were notified if the patient was discharged from the OMC which was
documented in CPRS OMC clinic note. PCPs were notified by telephone, face-to-face
communication or through the additional signer feature in CPRS that required the
recipient of the alert to electronically co-sign the note of the OMC discharge. Further,
OMC recommendations for future treatment were offered to the PCP. Patients meeting
the OMC discharge criteria were as follows: (a) use of stimulants such as cocaine, heroin
or methamphetamines on urine drug screen, (b) documented diversion of opioids through
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patient admission of opioid diversion, (c) negative urine drug screen on at least two
occasions for prescribed opioids with confirmation test ordered by OMC staff, and (d)
failure to comply with the treatment plan which may result in opioid treatment being
discontinued appropriately and thus resulting to discharge from the OMC; A patient
receiving chronic opioid therapy was required to comply with the treatment plan,
including diagnostic tests, specialty consultations, and other treatments ordered by the
VA PCP or OMC staff. Other discharge criteria included: (e) self-referral around local
non-VA primary care clinics or to other VAs in search of multiple providers to prescribe
opioids as documented by the Nevada/Arizona/Utah controlled substance monitoring
program database or CPRS record, (f) abusing, threatening or intimidating VA staff
members; and (g) overt drug seeking behaviors such as multiple requests for early refills
of opioid medications due to loss or self dose escalation or multiple visits to community
emergency rooms or local clinics to obtain opioid prescriptions. Patients who were
discharged from the OMC due to abuse/misuse of medications can be reconsidered for
readmission to the OMC after they have completed at least 6 months of ADTP therapy.
Objective 3.

At three months and six months of OMC operation, clinic

evaluations were done to assess the function of the OMC as it related to the specific goals
and clinic objectives. A follow up provider satisfaction evaluation was done through
SurveyMonkey at approximately six months of clinic operation. The online survey was
sent to all PCPs in VA Las Vegas on February 18, 2014. All PCPs in the VA-Las Vegas
belong to a primary care mail group. The survey was sent to the mail group via secured
VA email. A follow up email from the Chief of Primary Care was sent to all PCPs
encouraging participation in the survey a day after the original email that asked PCPs to
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participate in the online survey. Another email was sent to all PCPs in VA Las Vegas a
week after to encourage those who have not yet participated in the survey. When this
survey was sent, there were forty two (42) PCPs employed by the VA Las Vegas and all
forty two were eligible to participate in the study. Thirty PCPs responded to the survey
so the response rate for the provider satisfaction survey was 71%. In the initial needs
assessment survey, 80% of the PCPs responded to the survey.
In addition to the online survey, a three month and six month chart review were
also done for all patients in the OMC to obtain information and compare data from the
initial OMC admission to the latest OMC clinic note. The OMC is a CQI project in the
VA Las Vegas that was initiated and implemented due to the growing concern among
PCPs of opioid abuse and misuse among veterans on chronic opioid therapy. Evaluation
of the OMC as part of the CQI allowed for documentation of clinic effectiveness in
improving the quality of care provided to the veterans. Data obtained for this CQI
included scores from the pain Screening Tool, BPI short form, and any other provider
notes that were essential to evaluating the OMC including challenges and barriers to the
change process. The number of admitted patients to the OMC and the number of
discharges from OMC were also tallied including the number of participants in the OMC
study. Data of baseline number of opioid pills dispensed and its associated pharmacy
cost from about the same time period of the previous year were compared to the 3 month
period of the OMC operation to see if there was any difference between the two periods.
Data gathered were compared to evaluate for any differences between data set points as
appropriate.
Resources and Supports
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The following resources and supports within the VA-Las Vegas were utilized in
the operation of the OMC: (1) ADTP, (2) Integrated Pain, (3) Chief of Primary Care,
(4) Pharmacy Service, (5) Laboratory Service, (6) Nursing Service, and (7) Health
Administration Service.
Risks and Threats
Veterans opting to be discharged from the OMC and return to their PCP for
management of opioids can be a potential threat to the success of the OMC. In this
situation, the PCP who initially referred the patient to OMC was alerted via the VA
CPRS to advise the PCP of patient discharge from the OMC. Additionally, the PCP was
directly contacted via telephone or face to face interaction (if the PCP is in the same
clinic as the OMC) to discuss the discharge along with OMC recommendation for future
care of the discharged veterans.
Another possible threat to the success of the OMC would be PCPs not referring
their patients who are at high risk for opioid abuse/misuse. This was mitigated by the
delivery of multiple planned provider in-service informational sessions regarding the
OMC prior to initiation of the OMC and during the OMC implementation. Further, the
OMC staff sent regular notification messages via email to all PCPs of the availability of
the OMC and how the OMC can assist them in the management of patients on chronic
pain.
Lastly, PCP’s continued noncompliance with current guidelines in the
management of chronic pain with chronic opioid therapy could present a threat to the
effectiveness and success of the OMC. This was mitigated with leadership support and
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planned provider in-service sessions that addressed the importance of the OMC and
discussed recommendations from the current VA/DoD clinical practice guideline.
Marketing Plan
The OMC had strong support from leadership and was validated by the initial
needs assessment which showed that all PCPs who responded in the survey were
interested in the OMC to assist them in monitoring opioid use of patients on chronic
opioid therapy. The OMC staff provided an in-service to all PCPs through the scheduled
monthly PCP staff meeting. Advertisement of the OMC was done through email to all
healthcare providers in the VA-Las Vegas which included PCPs and other healthcare
providers. In addition to the email notification to PCPs, a flier was also developed and
posted in the Southwest Primary Care Clinic where the OMC was located.
Financial Plan
The OMC was implemented using current staffing. A teamlet consisting of an
APRN, a registered nurse, a licensed practice nurse and a medical clerk made up the staff
of the OMC (0.1 full time equivalent [FTE] Primary Care NP, 0.1 FTE Primary Care RN,
0.1 FTE Primary Care LPN, 0.1 FTE Medical Clerk) (See Appendix M for budget).
Institutional Review Board Approval
The Evaluation of an Opioid Monitoring Clinic study received IRB approval on
November 20, 2013. The study was approved through an expedited review process. As
soon as the study to evaluate the OMC received the IRB approval, the OMC immediately
started enrolling patients into the study. As of February 23, 2014, a total of sixty-one
patients were recruited and participated in the study. Additionally, as of February 28,
2014, a total of thirty PCPs have completed the online provider satisfaction survey sent to
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all VA Las Vegas PCPs on February 18, 2014. Twenty-six PCPs elected to participate in
the study and four elected not participate in the study. The online survey response rate
was 71%.
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CHAPTER 5
SUMMARY OF IMPLEMENTATION AND RESULTS
Initiation of the Project
The effectiveness of the OMC clinic was measured and evaluated through the use
of screening tools such as the BPI, Pain Screening Tool, PDMP, urine drug screens, and
opioid pharmaceutical costs. Based on the number of patients who were identified to be
abusing and misusing their opioid prescriptions, the OMC has shown effectiveness in
identifying veterans who were abusing and/or misusing their prescription opioids. These
patients were promptly referred for treatment in the ADTP or MHC.
The OMC was able to align chronic opioid use in accordance with the VA/DoD
clinical practice guideline for chronic opioid therapy as evidenced by self-report by PCPs
in the provider satisfaction survey of increased use of the Opioid Pain Agreement,
increased PCP compliance in the use of urine drug screens to monitor patients on chronic
opioid therapy, increased use of PDMP to monitor patients who may be “doctor
shopping”, and increased PCP report of compliance with the VA/DoD clinical practice
guideline for chronic opioid therapy. Additionally, patients who had no history of being
referred to other pain modalities such as physical therapy, physiatry, acupuncture,
chiropractor, interventional anesthesia injection, and/or osteopathic manipulation therapy
were recommended for referral to these clinics as an adjunct to pharmaceutical pain
management.
The opioid schedule of patients at admission were evaluated and if the current
opioid therapy was a combination of short acting and long acting opioids, an opioid
substitution from short acting opioids to a long acting opioid was recommended based on
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morphine equivalent calculation to reduce the number of pills and to reduce the use of
short acting opioids. If the patient was on short acting opioids only, the same opioid
substitution recommendation of changing from short acting to long acting opioids was
done. These strategies were consistent with the Va/DoD clinical practice guideline
(Department of Veterans Affairs and Department of Defense, 2010). The purpose of
using long acting opioids as opposed to short acting opioids was two-fold. First, the
substitution of long acting opioids can reduce the number of pills dispensed per month on
patients with high risk for abuse and misuse of opioids. High quantity of opioid pills
dispensed per month can be a factor in the decision to misuse or divert prescription
opioid medications (Gomes, Mamdani, Dhalla, Paterson, & Juurlink, 2011; Katz, ElGabalawy, Keyes, Martins, & Sareen, 2013). Second, long acting opioids can provide a
more stable pain management at longer duration than short acting opioids thereby
potentially eliminating the need to take extra doses when pain is at high intensity as seen
in patients taking short acting opioids.
At six months, the change process in implementing the OMC was evaluated as it
related to the project objectives. This evaluation consisted of the following: (1) Provider
satisfaction evaluation survey through SurveyMonkey which were sent to all PCPs in the
VA-Las Vegas for completion, and (2) A chart review completed for all patients admitted
in the OMC to obtain data and compare from the initial OMC admission note to the last
OMC clinic note. Data obtained included scores from the pain screening tool and BPI
short form, as well as other relevant information including challenges and barriers to the
change process, number of admitted patients to the OMC and the number of discharges
from OMC which were tallied, and baseline number of opioid pills dispensed with its
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associated pharmacy cost from about the same time period the year before compared to
the three month period of the OMC operation to see if there was any difference between
the two periods. For example, opioids dispensed by pharmacy between the months of
July to September 2013 (4th fiscal quarter) were compared to the same months in the prior
year (2012) and to the previous fiscal quarter (3rd fiscal quarter 2013) to evaluate any
change. All findings were reported to the VA-Las Vegas leadership on February 18,
2014.
Threats and Barriers to the Project
Despite strong leadership support of the development and implementation of the
OMC in the VA Las Vegas, there were unexpected delays that were encountered during
the implementation phase of the OMC. Bureaucratic delays in the actual implementation
of the consultation process into the electronic medical record resulted in extensive delay
in the full implementation of the clinic into the computerized electronic medical record.
The integration of the OMC consultation process into the electronic record was necessary
because it eased the notification and communication between the referring PCP and the
OMC staff. The integration also eased the accounting of all patients referred to the OMC
as each consult was associated with workload credit specific to the OMC that can be
easily be pulled from the CPRS for accounting purpose. The approval process for the
integration of the clinic into the electronic medical record had to come from many layers
of committee approvals. To compensate for the extensive delay in the approval process
of integrating the consult service of the OMC into the electronic medical record, a
temporary solution was implemented to start the clinic and see patients into the clinic
while the clinic electronic consult templates and associated clinical notes awaited formal
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approval from several committees in the VA Las Vegas. This was done through
advertising the clinic to clinic chiefs and PCPs of the existence of the OMC despite
current inexistence of a formal electronic consult to refer their patients to the OMC.
Referring providers were able to temporarily refer patients into the OMC by having the
APRN clinician in the OMC as an additional signer to their note that included a reason as
to why the referring clinician would like to refer their patient to the OMC. This workaround allowed the OMC to admit and evaluate patients into the clinic for monitoring
based on protocol. As soon as the electronic consult received final approval on February
12, 2014 from several layers of committees, the electronic consult was finally
implemented into the live system of the electronic medical record. The live consult was
activated in CPRS on February 13, 2014. The referring primary care providers were also
automatically notified of any activities in the electronic consultation such as new visits in
the OMC. This served as an effective line of communication between the OMC staff and
the referring primary care provider.
Even though the early results for the OMC were encouraging, some PCPs voiced
concern that even with the help of the OMC, the number of walk-in patients in the PCP
practice did not improve. This concern may not have any relationship with the OMC
since patient walk-ins may be for reasons other than for pain management or opioid
needs. One PCP who referred at least one patient to the OMC disagreed that he/she
received fewer complaints regarding pain medications. It was very likely that patients
referred to the OMC who had their opioids reduced/discontinued would be very unhappy
with the change in their opioid therapy and may have voiced their dissatisfaction with the
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change in their opioid therapy to their PCP who referred them to the OMC. These could
become barriers to continued PCP referral to the OMC.
It is also possible that PCPs who receive many patient complaints may give in to
patient requests to resume opioid therapy despite evidence of abuse and misuse of
opioids. PCPs may become overwhelmed with patient complaints and may opt to a “path
of least resistance” and succumb to patients request for opioids despite evidence of lack
of medical necessity for opioid therapy.
Monitoring of the Project
Besides effectiveness in identifying active illicit substance use, doctor shopping,
and other aberrant behaviors that can lead to opioid-related complications such as
accidental overdose and death, the OMC has also shown effectiveness in helping PCPs
become more aligned with the VA/DoD clinical practice guideline in the management of
patients with chronic pain and on chronic opioid therapy. The satisfaction among PCPs
who have referred patients to the OMC has been very positive. An overwhelming
number of PCPs who participated in the survey reported following the recommendations
by the VA/DoD clinical practice guideline in the regular use of urine drug screens and the
PDMP to monitor patients on chronic opioid therapy. Further, most PCPs reported
completing an Opioid Pain Agreement with their patients.
To maintain and sustain change, long term evaluations are necessary. A twelve
month evaluation will be done identical to the initial three months evaluation for this
project. Lastly, a patient satisfaction survey will be given to all patients admitted in the
OMC after one year of operation to assess their satisfaction with the OMC. If the goals
and objectives are met, continued operation and possible expansion of the OMC would be
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likely supported by the VA Las Vegas leadership. Further, the VA-Las Vegas pharmacy
cost for opioids will be compared with baseline (FY 2013 compared to FY 2014) to
continually monitor the effect of increasing use of urine drug screen, and PDMP. The
number of opioid pills dispensed will be compared between FY 2013 and FY 2014.
Also, the number of short acting opioids and long acting opioids will be compared
between FY 2013 and FY 2014.
Data Collection
All patients who were seen and evaluated in the OMC since the start of the clinic
implementation had an electronic health record of their visit in the OMC. Patients were
asked to complete the BPI questionnaires. In addition to the BPI questionnaires, patients
were interviewed regarding their pain history and their history of pain treatments.
Patients were also asked any history of substance abuse if none were documented in the
CPRS or in the PCP referral documentation. A suicide and homicidal risk assessment
was done on each patient and documented in the OMC clinic note. The MED was
calculated based on the current opioid therapy of the patient. Patients were asked about
the last opioid dose taken to correlate their responses with the amount of opioids patients
receive per month and their refill habits. A pain Screening Tool assessment was done on
each patient. All patients also had a PDMP inquiry. In addition to the PDMP, a urine
drug screen history was also searched in the electronic health record to document
previous urine drug screen results. All patients also were asked to submit a urine drug
screen as per OMC clinic protocol. All results were documented in the OMC clinic note
in the CPRS.
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When the study to evaluate the OMC was approved by the UNLV IRB on
November 20, 2013, the OMC immediately started enrolling patients to the study.
Eligible patients who were currently being seen in the OMC were asked to participate in
the study. New referrals from the PCPs who were eligible to participate in the study were
also asked to participate. All documentations were done in the VA CPRS.
Data Analysis
Pertinent patient data related to the OMC evaluation study were stored in secured
Microsoft Access for database record keeping. The database included patient ID, age,
gender, major source of pain, concurrent use of other controlled substances, presence of a
pain agreement prior to admission, presence of urine drug screen prior to admission,
MED prior to admission, MED at last visit, PDMP report, BPI scores, Pain Screening
Tool score, and retention outcome of patients seen and evaluated in the OMC. The
CPRS was reviewed for history of urine drug screen on record and its associated results,
history of aberrant behaviors including documented report of multiple requests for early
refills due to loss of opioid medications or requests for escalating dose for opioid
prescriptions. Additionally, a preliminary review of PDMP was also done to screen
patients prior to the initial visit. Once patients were seen and evaluated in the OMC,
some patients who were found to be abusing and misusing their opioid prescriptions were
informed of the findings with subsequent recommendations from the OMC. This
included a referral to the ADTP and discontinuation of opioid therapy when there was
evidence of multiple receipts of opioid prescriptions from both the VA and outside
pharmacies as reported by the PDMP, or by tapering (when there is evidence that the
patient was taking their opioids based on laboratory opioid confirmation but misusing).
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Patient outcomes in the OMC included those patients who were retained by the OMC for
continued monitoring and management of their opioid therapy; and patients who were
discontinued on opioid therapy due to discovery of abuse and misuse of opioids either at
the time of the initial visit and/or during the monitoring of the patient in the OMC. Data
from the Microsoft access were then imported to SPSS for data analysis. The SPSS
version used for this study was version 21. Statistical data analyses results were verified
by a biostatistician.
Table 1 shows the summary of all patients seen in the OMC whether they
participated in the OMC evaluation study or not. A total of one hundred fourteen (114)
veterans were seen and evaluated in the OMC from July 1, 2013 through February 18,
2014. Sixty-one (61) patients volunteered to participate in the study and signed the
informed consent. The average age of both participants in the study and the
nonparticipants was fifty-three (53) years old. There were four (4) female and fifty-seven
(57) male participants; and three (3) female and fifty (50) male nonparticipants.
The most common source of pain among nonparticipants and participants in the
OMC study was back pain. Forty-two nonparticipants (79%) reported back pain as the
major source of pain. For the study participants, thirty-eight (62%) reported back pain as
the major source of pain. Twenty-two (42%) nonparticipants and twenty-five participants
(41%) were on concurrent use of opioids and benzodiazepines. Thirty-six (68%)
nonparticipants and fifty-four participants (89%) had a signed a pain agreement prior to
being seen in the OMC. Forty-two (79%) nonparticipants and forty-nine participants
(80%) had a urine drug screen prior to being seen in the OMC. Sixteen (30%)
nonparticipants and twenty-three (38%) participants were found to have unexpected urine
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drug screens at their initial OMC visit or at subsequent OMC visits. Unexpected findings
in urine drug screen included positive findings for illicit substances in the urine including
methamphetamines, barbiturates, cocaine, heroin, and/or benzodiazepines when none
were expected, and negative opioid level in the urine drug screen even with confirmation
testing. Presence of other opioids in the urine such as methadone when methadone was
not being prescribed was considered an opioid abuse.

Table 1.
Summary of Study Participants and Nonparticipants (n=114)
Average
Age

Participants

Gender

Major
source of
Pain

53

M:57
F:4

Back
37(62%)

53

M:50
F:3

Back
42 (79%)

Concurrent
use of a
controlled
substance
25 (41%)

Prior Pain
Agreement

POS UDS

54(89%)

Prior
Urine
Drug
Screens
49(80%)

22(42%)

36(68%)

42(79%)

16(30%)

23(38%)

n=61
Nonparticipants
n=53

POS UDS=positive urine drug screens at initial OMC visit or later

Table 2 shows the breakdown of patients who tested positive in their urine drug
screens at their initial OMC visit. One patient participant (2%) had a combination of
illicit substance in their urine and negative opioid level despite being on active opioid
therapy. Nine participants (15%) had consistent negative opioid level in their urine even
with confirmation testing. Twelve participants (20%) were found to have illicit substance
in their urine. Among the nonparticipants, eleven patients (21%) were found to have a
combination of illicit substance and negative opioid level in their urine. Two
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nonparticipants (4%) had consistently negative opioid level in the urine and ten (19%)
were found to have an illicit substance in their urine.

Table 2
Summary of Study Participants and Nonparticipants that had Positive UDS
Type of Abuse

Participants

Nonparticipants

n=23

n=16

Combination of SA/Neg

1(2%)

11(21%)

Negative Opioid

9(15%)

2(4%)

Substance Abuse

12(20%)

10(19%)

SA/Neg= combination of substance abuse and negative opioid level

Table 3 shows the number of patients seen in the OMC who were found to have
been “doctor shopping”. Twelve (20%) patient participants and sixteen (30%)
nonparticipants were found to be “doctor shopping”.

Table 3
Patients found to be “Doctor Shopping”
Participants

Nonparticipants

n=61

n=53

12(20%)

16(30%)

Table 4 shows the change in MED per day before admission to the OMC and after
admission to the OMC. Prior to evaluation and admission to the OMC, the average
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morphine equivalent dose (MED) per day among the participants was 96mg per day.
After admission to the OMC, the average MED went down to 46mg per day, a 52%
reduction in MED. For OMC nonparticipants, the before admission average MED was
80mg per day and the after admission average MED was 45mg per day, 44% reduction in
MED. The large drop in the MED between before admission and after admission was
mainly from the discontinuation of opioids due to discovery of abuse and misuse of their
opioids among patient participants in the OMC study. Using the exact single-tailed
Wilcoxon Signed- Rank Test, the before and after MED difference was found to be
highly significant with a p<.001. Further analysis was done with MED category by
comparing to see if there was any difference between the patients who participated in the
OMC study and those who did not. The Mann-Whitney test was used to compare the
change in MED among OMC participants and nonparticipants. There was no difference
between the two groups (p=.830). The OMC was able to reduce the MED per day among
all patients seen in the OMC regardless of study participation.

Table 4
Morphine Equivalent Dose (MED) Comparison Between Participants and
Nonparticipants

Participants
Nonparticipants

MED per day
prior to
admission
96mg

MED per day
after admission

Change in
MED

p-value

46mg

-48%

p<.001

80mg

45mg

-54%

P<.001
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Table 5 shows the retention outcomes of OMC participants. Thirty-nine (64%)
individuals remained as patients in the OMC and continued to be monitored by the OMC.
Twenty-two (36%) participants had their opioids discontinued due to discovery of active
illicit substance use, “doctor shopping”, opioid abuse, noncompliance with the treatment
plan and/or self-decision to discontinue opioid therapy. Of those who had their opioids
discontinued, twelve (20%) were referred to the ADTP according to the protocol due to
either the discovery of illicit substance use or the discovery of “doctor shopping”; nine
(15%) were referred to the Integrated Pain Clinic for non-opioid pain management, and
one patient (2%) decided to discontinue their opioids on their own and self-discharged
from the OMC. Among nonparticipants, eleven patients (21%) were continued to be seen
and monitored in the OMC. Seventeen patients (32%) were referred to the Integrated
Pain Clinic, eighteen patients (34%) were referred to ADTP, and seven (13%) transferred
to another PCP and did not return for follow up with the OMC. All patients discharged
from OMC including those who decided to discontinue their opioid therapy on their own
had their CPRS record reviewed by the OMC staff to document if any of them ended up
returning on opioid therapy by their referring provider or another PCP if they transferred
to another PCP. At the time final data collection was done on February 23, 2014, none of
the patients who were discharged from the OMC were known to resume their opioid
therapy with their PCP (or new PCP if they transferred) or with the pain clinic. The
planned one year follow up evaluation of the OMC would provide better outcome data of
what ends up happening to these patients after they were recommended for
discontinuation of opioid therapy.
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Table 5
Retention Outcomes of Patients in the OMC Study (n=114)
Outcomes

Participants

Nonparticipants

(n=61)

(n=53)

#

%

#

%

Retained in OMC

39

64%

11

21%

Discharged to ADTP

12

20%

18

34%

Discharged to Pain Clinic

9

15%

17

32%

Transferred to new PCP

0

7

13%

Self-discontinuation of
opioid

1

2%

0

To evaluate whether there is any relationship between patient retention outcomes
among all patients seen in the OMC and the Pain Screening Tool as well as the BPI, a
Chi-Squares test was done (Table 6). Since majority of the Pain Screening Tool scores
were less than three, the Likelihood Ratio Chi-Square Test was used to determine the
relationship between the two variables.
Table 6 shows the relationship between the Pain Screening Tool, BPI and OMC
patient retention outcomes. The relationship between the Pain Screening Tool scores and
patient retention outcomes (continuation in the OMC or discharged from OMC) were
found to be significantly correlated (p=.006). In order to examine this further, Screening
Tool scores 0-2 were recoded in SPSS as one category of score and scores 3 and higher
were recoded as another category. There were two reasons for this recoding. First, the
sample size for scores equal or higher than 3 was small. The second reason for the
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recoding of data was due to previous work by Atluri and Sudarshan (2004) that found
scores 3 and higher were of clinical significance to determine risk of abuse and misuse of
opioids. The authors in their development and validation study for the Pain Screening
Tool found that those who scored 3 and higher were at high risk for abuse and misuse of
opioids. With the recoding, the Pain Screening Tool scores were found to be highly
correlated to patient retention outcomes (p=.003) using the Likelihood Ratio Test (LR).
The Pain Screening Tool score was also found to be highly correlated to patients who
were discharged from the OMC due to abuse and misuse of opioids (LR p<.001). This
means that the Pain Screening Tool scores of patients seen in the OMC correlated well
with what happened to patients seen in the OMC. In other words, patients who scored
less than 3 in the Pain Screening Tool were likely to be retained by the OMC for
monitoring due to compliance with opioid therapy and absence of adverse findings such
as abuse and misuse of opioids. Similarly, patients who scored at least 3 on the Pain
Screening Tool were likely to be discharged from the OMC due to discovery of abuse
and misuse of opioids.
Using LR, there was no significant relationship between admission BPI pain
intensity score and patient retention outcomes (p=.162) for all patients seen in the OMC.
There was also no significant relationship found between BPI functional intensity and
patient retention outcomes (p=.084) for all patients seen in the OMC. Additionally, there
was no significant relationship found between all OMC patients who were abusing their
opioids, “doctor shopping”, and/or actively using illicit substance based on urine drug
screen and the admission BPI pain intensity score (LR p=.275). The BPI functional
intensity score was also not found to be significantly correlated to all OMC patients who
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were found to be abusing their opioids, “doctor shopping”, and/or actively using illicit
substance (LR p=.149). Participation in the OMC study was also analyzed to see if
participation in the study was related to patient abuse and misuse of opioids. The
relationship between OMC participation and patient abuse and misuse of opioids was
found to be unrelated (LR p=.374).
These results indicated that data analyses of BPI scores of patients seen in the
OMC and patient outcome (patient retention and discharge from OMC) were found to be
unrelated. Patients who scored low for either the pain or functional intensity of the BPI
was not associated with being retained in the OMC. Similarly, patients who scored high
for either the pain or functional intensity of the BPI was not associated with being
discharged from the OMC due to abuse and misuse of opioids. Less than half (49%) of
patients seen in the OMC had an assessment for BPI scoring. This likely affected data
analyses.

Table 6
Relationship between Pain Screening Tool/BPI and Patient Retention Outcomes

Patient Outcomes and Pain Screening Tool Score

P-value
0.003

Discharged from OMC and Pain Screening Tool score

<0.001

Patient Outcomes and BPI pain intensity score

0.162

Patient Outcomes and BPI functional intensity score

0.084

Discharge from OMC and BPI pain intensity score

0.275

Discharge from OMC and BPI functional intensity score

0.149
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Table 7 shows the number of patients who were identified by the OMC to be
abusing or misusing their opioids which resulted in the discontinuation of their chronic
opioid therapy. A total of twenty-six (43%) of participants and twenty-seven (51%)
nonparticipants were discontinued from opioid therapy. Thirteen participants (21%) and
eight (15%) nonparticipants were found to be actively using an illicit substance such as
cocaine, heroin and/or marijuana. Nine participants (15%) and twelve nonparticipants
(23%) were found to be “doctor shopping”. Three participants (5%) and six
nonparticipants (11%) were found to be abusing an opioid other by having an opioid in
their urine that is different from the one they were prescribed or by having hospital
admissions related to opioid overdose. Patients who were admitted to the hospital for
opioid overdose were automatically followed by the mental health clinic as per VA
policy upon discharge from the hospital. One patient from the nonparticipant group was
admitted in the hospital for opioid overdose. One participant (2%) was found to be
“doctor shopping” and using an illicit substance. One nonparticipant (2%) had
consistently negative opioids which resulted in the discontinuation of opioid therapy by
the OMC. All patients who were found to be actively using an illicit substance and/or
“doctor shopping” had their opioids discontinued either immediately, as appropriate, or
by tapering. These patients were also discharged from the OMC and were referred to the
ADTP, pain psychology, and/or the Integrated Pain Clinic for evaluation and proper
treatment.
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Table 7
Comparison of Opioid Abuse and Misuse Among OMC Participants and Nonparticipants
Reasons for Opioid
Discontinuation

#

%

Illicit Substance Abuse

13

21%

“Doctor Shopping”

9

15%

Opioid Abuse

3

5%

Combination SA/DD

1

2%

Illicit Substance Abuse

8

15%

Nonparticipants

“Doctor Shopping”

12

23%

N=27

Opioid Abuse

6

11%

Negative Opioids

1

2%

Combination SA/DD

1

2%

Participants
N=26

Combination SA/DD=Substance abuse and “Doctor Shopping”

The BPI data collected on patients admitted in the OMC and enrolled in the OMC
study were also analyzed (Table 8). The scoring for both the pain intensity and
functional assessment of the BPI is based on the 0-10 scoring system. For the pain
intensity portion of the BPI, 0 means no pain and 10 means worse pain they can imagine.
For the functional assessment portion of the BPI, 0 means that their pain does not
interfere with the function-related questions in the BPI and 10 means that pain
completely interferes with the function-related questions in the BPI.
There were 56 patients seen in the OMC who had a BPI scoring in the CPRS
record. There were 22 patients who had subsequent BPI scoring after the initial visit.
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The reason for the difference in the number of BPI assessments between the initial visit
and the follow up visits was because many of patients seen in the OMC for the initial
visit were recommended for immediate discontinuation of opioids such as those who
were found to be “doctor shopping” and/or those who were found to have positive urine
drug screens for illicit substance at the time of referral to the OMC. Most of these
patients were discharged from the OMC in a single OMC visit and did not return for
OMC follow up. Many of the patients who did not want to participate in the OMC study
and did not want to be seen in the OMC after explanation of the reason for referral and
purpose of the OMC did not have a complete documentation of visit as per OMC clinic
note due to patient refusal to complete the BPI questionnaires or lack of time during the
visit to assess the BPI scores. Additionally, many patients who had missing BPI
assessments tend to be patients who were referred to the OMC during the first few weeks
of the OMC operation where clinic efficiency was still in infancy. Patients who were
referred in the OMC after the OMC electronic consult was approved along with its
associated clinic notes had complete documentation in CPRS. Patients who did not have
a complete documentation in the OMC had their data reviewed by the OMC through
CPRS chart review for data collection. Lastly, patients who were seen in the OMC and
had initial BPI assessments were captured for BPI reassessment only after they returned
for follow up visits. In the OMC, follow up visits can range from weekly to every three
months.
The average admission BPI pain intensity score for all 56 patients seen in the
OMC was 6.3. The average BPI pain intensity score dropped to 5.8 after patients were
seen in the OMC. For the functional pain assessment, the average admission BPI score

65

for the functional portion of the BPI was 6.3. In similar fashion as with the pain intensity
assessment, the average functional BPI score at latest patient OMC visit decreased to 5.8.
Table 7 shows the data analysis of BPI scores at admission and comparing it to the BPI
scores with the latest patient visit using the exact 1-tailed Wilcoxon Signed-Rank test
because the data was normally distributed and the sample was small. When comparing
before and after pain intensity score of the BPI for all patients seen in the OMC, there
was no significant difference between the two groups (p=.090). When comparing before
and after functional intensity of the BPI for all patients seen in the OMC, there was also
no significant difference between the two groups (p=.389).

Table 8
Comparison of Pre and Post BPI scores among all patients seen in OMC
PreBPI-Post BPI pain intensity

p=.090

PreBPI-Post BPI functional intensity

p=.389

The OMC has shown effectiveness in identifying abuse and misuse of opioids
through intensive urine drug screening and PDMP inquiry to discover “doctor shopping”.
The identification of abuse and misuse of opioids among veterans resulted in the
discontinuation of their chronic opioid therapy. Additionally, patients who continue to be
monitored in the OMC were also recommended to change their opioid therapy from using
short acting opioids to using long acting opioids as much as possible. The combination
of discontinuation of opioids among patients who were found to be abusing and misusing
their opioids coupled with the decrease in pill burden with the change from short acting
66

to long acting opioids resulted in significant savings for the VA Las Vegas. Table 9
shows the quarterly cost of opioid utilization in the outpatient clinics of VA Las Vegas.
In the 4th Quarter Fiscal Year 2013 (July-September), the VA Las Vegas spent $241,166
for pharmaceutical costs of the six most commonly prescribed opioids in VA Las Vegas
(in order of frequency- Hydrocodone, Oxycodone, Morphine, Percocet, Tylenol with
codeine, and Methadone). For the 1st Quarter Fiscal Year 2014 (October-December), the
pharmaceutical cost for the same six most commonly prescribed opioids in VA Las
Vegas increased to $310,926. The fiscal year 2012 quarterly cost for the same six opioids
was $235, 280. VA Las Vegas data on opioid pharmaceutical cost for the top 6 most
commonly prescribed opioids in primary care shows an increasing pharmaceutical cost
even before the OMC was initiated in the VA Las Vegas. There are several possible
explanations for this. First, it is possible that there were more patients who were on
opioid therapy. Second, it is also possible that the cost for these opioids has been
increasing and that may account for the increasing opioid pharmaceutical cost.

Table 9
Top 6 Opioids Cost to VA Las Vegas for 2 Quarters Compared to Fiscal Year 2012
Quarterly Cost
Opioid

Hydrocodone
Oxycodone
Morphine
Oxycodone/APAP
APAP/Codeine
Methadone
Total

4th Qtr
FY 2013
Cost $
$69,293
$137,176
$23,529
$4,809
$2,640
$3,719
$241,166

Qtrly
FY 2012
Cost $
$68,991
$132,637
$24,327
$4124
$2429
$2772
$235,280
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1st Qtr
FY 2014
Cost $
$146,484
$128,702
$4,376
$4,376
$2,794
$3860
$310,924

The increase in the number of urine drug screens being ordered in the VA Las
Vegas is very encouraging. The number of urine drug screens that are ordered in the VA
Las Vegas continued to increase quarterly (Figure 7). Prior to implementation of the
OMC, 1606 urine drug screens were ordered in VA Las Vegas for the period of three
months (April 1, 2013 through June 30, 2013). This number has been steadily increasing
since the implementation of the OMC. From July 1, 2013 through September 30, 2013,
there were 1849 urine drug screens ordered in VA Las Vegas or an increase of 13% from
the previous quarter. From October 1, 2013 through December 31, 2013, the number
increased further to 2293 urine drug screens ordered for the 1st quarter fiscal year 2014 or
an increase of 19%. Since the start of the OMC in July 2013 though the end of December
2013, the number of urine drug screens ordered in the VA Las Vegas increased by 30%.
The cost for each urine drug screen in VA Las Vegas is $9.00. The associated cost of
doing urine drugs for the 114 patients seen in the OMC was $1026. The associated cost
with the increase in the overall urine drug screens ordered in the VA was $6183 (2293
urine drug screens ordered in 1st quarter fiscal year 2014 minus 1606 urine drug screens
ordered in 3rd quarter fiscal year 2013 equal 687 more urine drug screens x $9.00). The
number of urine drug screens ordered in the VA Las Vegas was expected to go up as
more PCPs follow the VA/DoD clinical practice guideline to monitor their patients on
chronic opioid therapy. However, the increased cost associated with ordering more urine
drug screens is dwarfed by the potential cost saving from preventing even one patient
from a complication of opioid abuse such as an opioid overdose as each opioid abuse is
estimated to cost a minimum of nearly $29,000 for each patient (Baser et al., 2013).
Additionally, the associated cost of the increase in urine drug screens likely was offset by
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the associated opioid pharmacy cost from the discontinuation of opioids due to discovery
of abuse and misuse of opioids.

# of UDS Ordered
2500
2000
1500
1000

# of UDS Ordered

500
0
Number of UDS Number of UDS Number of UDS
ordered (3rd Qtr ordered (4th Qtr ordered (1st Qtr
FY 2013)
FY 2013)
FY 2014)

Figure 7. Quarterly data of urine drug screens ordered by clinicians in VA Las Vegas. 3rd
Qtr FY 2013=April 1, 2013 to June 30, 2013; 4th Qtr FY 2013 =July 1, 2013 to
September 30, 2013; 1st Qtr FY 2014=October 1, 2013 to December 31, 2013;
UDS=urine drug screen.

The increasing trend in the use of urine drug screens among PCPs is a very
encouraging result. To explain this trend, a provider satisfaction survey was sent to all
PCPs in VA Las Vegas on February 18, 2014. Table 10 shows the results of the provider
satisfaction survey. Thirty of the forty-two eligible PCPs (71%) completed the survey.
Twenty-six PCPs participated in the study. Four PCPs elected not to participate in the
study but all four responded to the questions in the survey.
A total of twelve PCPs (40%) out of the thirty PCPs who responded in the survey
reported that they have referred at least one patient to the OMC and eighteen (60%)
reported that they have not yet referred a patient to the OMC. Twenty-seven (90%) PCPs
reported that they follow the VA/DoD clinical practice guideline for chronic opioid
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therapy. Three PCPs (10%) responded with a neutral response to the Likert-type
question. Among PCPs who responded that they have referred at least one patient to the
OMC, all twelve (100%) reported that they follow the VA/DoD clinical practice
guideline.
When it comes to the use of opioid pain agreement, twenty-four PCPs (80%)
responded that they use the Opioid Pain Agreement more often than the previous 12
months. Five of the PCPs (17%) responded neutral to this question and one PCP (3%)
disagreed that he/she uses the Opioid Pain Agreement more often than the previous 12
months. Among PCPs who responded that they have referred at least one patient to the
OMC, eleven (91%) reported that they use the Opioid Pain Agreement more often than
the previous 12 months.
When it comes to the use of urine drug screens, twenty-seven (93%) of the PCPs
responded that they routinely order a urine drug screen for their patient on opioid therapy.
Two PCPs (7%) responded neutral to this question and one PCP did not respond to this
question. Among PCPs who responded that they have referred at least one patient to the
OMC, all twelve (100%) reported that they follow the routinely order a urine drug screen
for their patient on opioid therapy.
Sixteen PCPs (54%) responded that they routinely access the PDMP to check for
“doctor shopping”. Seven PCPs (23%) responded neutral to this question and seven
PCPs (23%) disagreed that they routinely access the PDMP. Two PCPs left a comment
in this question that both were unable to access the PDMP because they have not signed
up yet for access to the PDMP. Among PCPs who responded that they have referred at
least one patient to the OMC, eight (67%) reported that they routinely access the PDMP.
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The use of PDMP to screen patients on opioid therapy is an important strategy to identify
patients who are “doctor shopping”.
The percentage of PCPs reporting that they follow the VA/DoD clinical practice
guideline in this subsequent survey is an improvement from the baseline survey when
only 58% of PCPs who participated in the survey reported that they follow the VA/DoD
clinical practice guideline. The number of PCPs reporting that they are using the Opioid
Pain agreement more to manage their patients on opioid therapy is an encouraging result
from this survey as it further provides support that PCPs are following the
recommendations from the VA/DoD clinical practice guidelines. Furthermore, more than
half of the PCPs who responded to the survey reported using the PDMP to screen their
patients on opioid therapy. This is also an encouraging result since 25% of patients seen
and evaluated in the OMC were found to be “doctor shopping”. By accessing the PDMP
to screen their patients on opioid therapy, PCPs can help identify and stop abuse and
misuse of opioids as early as possible with subsequent referral for treatment as indicated.
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Table 10
Results of Provider Satisfaction Survey from all PCP Respondents (n =30)
I would like to participate in the study to evaluate the Opioid Monitoring Clinic
Yes
26 (87%)
No
4 (13%)
Have you referred patients to OMC?
Yes
No

12 (40%)
18 (60%)

I follow the recommendations in the VA/DoD Clinical Practice Guideline for Chronic
Opioid Therapy.
Strongly Agree/Agree
27 (90%)
Neutral
3 (10%)
Disagree
I use the Opioid Pain Agreement more often than the previous 12 months?
Strongly Agree/Agree
24 (80%)
Neutral
5 (17%)
Disagree
1 (3%)
I routinely order urine drug screens when indicated.
Strongly Agree/Agree
27 (93%)
Neutral
2 (7%)
Disagree
I routinely access a Prescription Drug Monitoring Program (PDMP) to check for double
dipping or “Doctor Shopping”.
Strongly Agree/Agree
16 (54%)
Neutral
7 (23%)
Disagree
7 (23%)

Table 11 shows the results of PCPs who elected to participate in the OMC study
and have referred at least one patient to the OMC (n = 11). Ten (91%) PCPs who
responded think that the OMC has a positive impact on the Primary Care practice. One
PCP (9%) responded neutral to this question.
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Six PCPs (55%) who have referred at least one patient to the OMC responded that
they have received fewer complaints regarding pain medications since they started
referring patients to the OMC. Four PCPs (36%) responded neutral to this question and
one PCP (9%) responded that they disagreed about having fewer complaints since they
started referring patients to the OMC.
Seven PCPs (64%) who referred patients to the OMC responded that they had
fewer patient walk-ins for pain management issues since they started referring patients to
the OMC. Five PCPs (36%) responded neutral to this question. One PCP left a comment
in this question that “we still gets lots of walkins for pain mgt issues.”
Ten PCPs (91%) who referred at least one patient to the OMC responded that they
were able to spend more time with the patient’s other medical problems when their
patients on opioid therapy were followed by the OMC. One PCP (9%) responded neutral
to this question.
All eleven PCPs (100%) who referred at least one patient to the OMC reported
overall satisfaction with the OMC in helping them manage their patients on chronic
opioid therapy. The baseline needs assessment survey that was done in January 2013
indicated the need for the OMC clinic as all PCPs who responded in that survey indicated
interest in the OMC. In this follow up survey, it appears that PCPs who have referred a
patient to the OMC are benefiting from service that the OMC has provided to their
patients.
Lastly, nine (82%) PCPs who referred patients to the OMC did not find anything
in the referral process that needed improvement. Two PCPs (18%) left a comment to this
question that the OMC was, “simple, easy and accessible” and that the referral process
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was “so far, it is great”. Another PCP left a comment, “I want patients who are suicidal
but still need pain control with narcotics to be addressed.”
PCPs who have referred patient in the OMC were reporting satisfaction with the
both referral process associated with the OMC as well as with the purpose of the OMC to
assist them in the management of high-risk patients on chronic opioid therapy. It was
expected that PCPs may be contacted by patients who were seen in the OMC and had
their opioid therapy switched to a longer acting opioids or had their opioid therapy
discontinue due to discovery of abuse and misuse of opioids. In an attempt to resume
opioid therapy, patients may walk-in and/or complain more to their PCPs due to their
perception of dissatisfaction of care they received from OMC. These behaviors were
expected but with high buy-in among PCPs for the OMC coupled with their concerns for
chronic opioid therapy for high risk patients, PCPs stood fast against reinitiating opioid
therapy on patients discontinued on opioid therapy due to discovery of opioid abuse and
misuse. At the time data was collected on February 23, 2014, patients who were
discontinued on opioid therapy by the OMC were still not on opioid therapy. Long-term
follow up data would be helpful to examine if opioid therapy are re-initiated at a later
point.
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Table 11
Results of Provider Satisfaction Survey: PCPs who participated in the OMC study and
has referred Patients in the OMC (n =11).
The service has a positive impact on the Primary Care service.
Strongly Agree/Agree
10 (91%)
Neutral
1 (9%)
Disagree
I receive fewer complaints regarding pain medications.
Strongly Agree/Agree
6 (55%)
Neutral
4 (36%)
Disagree
1 (9%)
There are fewer walk-ins for pain management issues.
Strongly Agree/Agree
7 (64%)
Neutral
4 (36%)
Disagree
I can spend more time with patient’s other medical problems when they are being
followed by this service.
Strongly Agree/Agree
10 (91%)
Neutral
1 (9%)
Disagree
Overall, are you satisfied with the Opioid Monitoring Clinic in helping you manage
chronic pain patients?
Strongly Agree/Agree
11 (100%)
Neutral
Disagree
Do you find anything in the OMC referral process that needs improvement?
Yes
2 (18%)
No
9 (82%)

Giving Meaning to the Data
The implementation of the OMC in the VA Las Vegas has shown great promise in
identifying abuse and misuse of prescription opioids among patients at high risk for abuse
and misuse opioids as reported in published literature (Ives et al., 2006; Manchikanti et
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al., 2012; Starrels et al., 2011; Wiedemer et al., 2007; Worley, 2014). The positive
results from the evaluation of the OMC can help ensure the continued support from VA
Las Vegas leadership.
Patients referred in the OMC had risk factors that put them at high risk for abuse
and misuse of opioids. The OMC was able to identify abuse and misuse in sixty-seven
(59%) of all patients referred and evaluated in the OMC. The finding is similar to the
study by Wiedemer et al. (2007) that reported 55% opioid abuse rate among patients
referred to the ORC. Additionally, the findings from the OMC evaluation also supported
Wiedemer et al.’s, 2007 findings of increased use of urine drug screens among PCPs and
increased PCP satisfaction. OMC patients who were found to be abusing and misusing
their opioid prescriptions were promptly referred to specialty care for further
management. When patients who abuse and misuse their prescription opioids are
discontinued on opioid therapy, the risk of them having opioid-related complications such
as opioid overdose and even death become much less (Trescot et al., 2006). Lastly,
opioids that were potentially being diverted by patients through “doctor shopping” and
possibly by patients with consistent negative opioid level in their urine were discontinued
from opioid therapy by the OMC. These opioids have the potential to reach someone
who may not be familiar with the use of an opioid and result in opioid-related
complications including death.
The OMC was able reduce the morphine equivalent dose per day for patients seen
and evaluated in the OMC regardless of their participation in the OMC study. The
average MED per day for all patients seen in the OMC dropped by 43mg. A rough
estimate of what this average drop in MED can be represented by multiplying this drop
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by the number of patients seen in the OMC. The calculated number can be applied to the
average opioid concentration that might have been stopped as the result of the discovery
by the OMC of substance abuse and “doctor shopping”. In this case, multiplying 43mg
by the 114 patients seen in the OMC would yield around 4,900mg MED of opioids that
were stopped as the result of the OMC’s strategy to identify patients who may be abusing
and misusing their prescription opioids. The calculated 4,900mg MED of opioids is
equivalent to about 980 hydrocodone 5/325mg pills. This means that for each month
after the OMC identified a patient who was abusing their opioid prescription and
discontinued their opioid therapy, the VA Las Vegas gets to dispense 980 less pills of
hydrocodone 5/325 per month. In a year, nearly 11,800 hydrocodone 5/325mg pills can
be prevented from being dispensed for inappropriate use by the VA Las Vegas due to the
direct action by the OMC. Besides the decrease in the number of opioid pills, the
healthcare cost savings associated with each veteran who was discontinued on opioid
therapy is much higher. According to Baser et al. (2013), each veteran on opioid therapy
who abuse their prescription opioids cost the VA approximately $29,000. There were
forty-five patients who were discontinued on opioid therapy because of the mitigation
strategies involved with the OMC. By multiplying 45 (number of patients discontinued
on opioid therapy) with $29,000, the potential savings of more than $1.3 million for early
identification of abuse and misuse of opioids may be estimated. The savings come from
preventing opioid-related complications to occur by stopping the use of inappropriate
opioids in the first place as recommended by Federation of State Medical Boards (2013).
This number was just from the OMC. Since there is evidence of higher compliance
among PCPs in following the VA/DoD clinical practice guideline in the management of
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patients on chronic opioid therapy, it is probably safe to say that PCPs who follow the
guideline are also discovering abuse and misuse of opioids among their patients who
were not referred to the OMC. When the cost savings from the number of patients who
were stopped on opioid therapy by their PCPs and by the OMC are added up, the
potential cost saving to the VA Las Vegas is likely to be much higher than the estimated
cost savings from OMC alone. The potential cost saving to the VA Las Vegas due to
discovery of abuse and misuse of opioids can be approximated based on the 3% five-year
prevalence rate of opioid abuse and $29,000 annual healthcare cost of veterans who
abused their opioid prescriptions that Baser et al. (2013) published. There were nearly
5,900 veterans on opioid therapy when the OMC was initiated. Based on the 3% 5-year
prevalence rate that Baser et al. (2013) reported and the 5,900 veterans on opioid therapy,
approximately 177 new cases of abuse and misuse of opioids might be identified by
regular opioid monitoring every 5 years (5,900 x 3%). The 5-year potential savings to
the VA Las Vegas based on this number is about $5.1 million every 5 years (177 x
$29,000).
The effectiveness of the OMC in improving the pain scores of patients seen in the
OMC is still unclear and too early to be determined. The planned evaluation at 12
months of the OMC operation may provide a better insight as to the effectiveness of the
OMC in improving BPI pain scores of patients seen in the OMC. Even though the
difference between the BPI scores at admission and BPI scores at the latest OMC
appointment was not significant, the clinical trend of lower pain intensity and functional
intensity scores from the BPI are encouraging. Further, early results from the OMC
evaluation showed that the Pain Screening Tool was highly related to patient retention
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outcomes of patients seen in the OMC. The evaluation also found that BPI scores were
not related to patient retention outcomes of patients seen in the OMC. One viable
explanation in the difference in the relationship between the two instruments used in the
OMC is that the Pain Screening Tool is based on clinician objective input while the BPI
is based on patient subjective input. A clinician with expertise in detecting opioid abuse
and misuse by thoroughly reviewing medical record and using specific patient questions
(i.e. “as the last time you took your opioid medications”, “describe to me your usual
intake of prescription opioid including timing and how many tablets you take with each
dose”) to correlate chart review (refill pattern and results of screening) with patient
responses to these questions would expectedly result to high correlation between the Pain
Screening Tool scores and patient retention outcomes. In contrast, BPI scores are based
on patient input to questions included in the BPI instrument. Patients who abuse and
misuse their medications or unhappy with the change in their opioid therapy may be
exaggerating their pain intensity and functional intensity to avoid changes in the current
opioid therapy. For example, patients found to be abusing and misusing their opioids and
were on slow tapering dose of opioids to avoid withdrawal symptoms tend to have higher
BPI pain intensity and functional intensity scores at follow up visits. These patients tend
to also report better pain relief with the use of short acting opioids. Future evaluation of
BPI scores in patients seen in the OMC should probably exclude those patients who were
found to be abusing and misusing their opioids and only include those who were
complying with the recommendations by the OMC and continue to be monitored by the
OMC. By including only the patients who continued to be monitored by the OMC, BPI
scores at admission and at one year after admission should likely provide a better insight
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as to how effective the OMC in improving pain outcomes for patients over time.
Improved pain scores in the BPI has been shown to correlate well with improved overall
pain management quality of patients with pain (Cleeland & Ryan, 1994).
Many patients seen in the OMC did not have complete OMC documentation
according to the OMC clinic note. Half (49%) did not have any BPI scoring done which
may have affected the data analyses related to BPI scores and its association with patient
retention outcomes. Many patients who did not have BPI scoring done were patients
seen very early in the OMC operation where scheduling conflicts and specific steps
involved with each OMC visit were still unfamiliar to the OMC staff. Since the full
implementation of the OMC in February 2014, all patients referred to the OMC and seen
in the OMC had full completion of the OMC clinic note.
The pharmaceutical cost for opioid use in VA Las Vegas has been going up even
before the initiation of the OMC. There are several reasons for the increasing trend in the
opioid pharmaceutical cost for the VA Las Vegas. First, the cost of these opioids may
have gone up to account for the higher cost for opioids from one quarter to the next.
Second, the number of veterans enrolling in the VA Las Vegas continues to increase, and
many of these newly enrolled veterans are young veterans with chronic pain. According
to a recent study, 50% young veterans coming from the Iraqi and Afghanistan wars have
chronic pain symptoms (Hoge & Castro, 2012). Many of these veterans enrolling in the
VA healthcare system also suffer from Post Traumatic Stress Disorder (PTSD). Research
has shown that nearly 86% of veterans with PTSD also suffer chronic pain (Vasterling et
al., 2010). The continued increase in the number of newly enrolled veterans coming in
the VA Las Vegas healthcare system coupled with high percentage of these veterans with
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chronic pain might be the reason for the continued rising cost of opioids in the VA Las
Vegas despite increased awareness among PCPs to monitor their patients on opioid
therapy for opioid abuse and misuse.
The increased opioid pharmacy cost noted in the OMC is counter to what has
been reported in by Wiedemer et al. (2007) and Kharlamb (n.d.) which reported
significant pharmacy cost savings from the implementation of an opioid renewal clinic
and substitution from short acting opioids to long acting opioids in patients on chronic
opioid therapy. It is noteworthy to point out that the OMC was able to stop opioid
therapy among patients found to be abusing and misusing their prescription opioids and
reduced the MED of patients referred to the OMC. The discontinuation of opioid therapy
and reduction in dose of opioids resulted in immediate cost saving to the VA Las Vegas.
The increase in compliance of PCPs in following the recommendations from the
evidenced-based VA/DoD clinical practice guideline is a very encouraging finding.
According to Trescot et al. (2006), compliance with clinical practice guidelines can help
reduce opioid-related complication. The use of urine drug screens in the VA Las Vegas
continue to increase as evidenced by increasing number of urine drug screens ordered by
clinicians in the VA Las Vegas. The use of the Opioid Pain Agreement and PDMP by
PCPs has also shown a dramatic improvement from the baseline needs assessment.
Based on these findings, PCPs appear to be more adherent in following the
recommendations from the VA/DoD clinical practice guideline.
The ease and effectiveness of the OMC also has led to a strong essential buy-in
among PCPs in helping them manage their high risk patients. PCPs who referred
patients into the OMC were very satisfied with the OMC and reported high satisfaction
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with the OMC referral process. Buy-in from PCPs is essential in the continued success of
the OMC as the OMC is dependent on PCPs continually referring high-risk patients to the
clinic.
Lastly, the development, implementation, and evaluation of the OMC were based
on Lewin’s Change Theory. By using Lewin’s Change Theory as its theoretical
framework, the OMC was able to develop and implement the clinic in a structured and
evidenced-based fashion. In the unfreezing phase, the OMC used all available evidence
as its driving forces to develop and implement the clinic, including a baseline needs
assessment survey done on PCPs and the growing problem of opioid abuse among
patients on chronic opioid therapy. To address possible restraining forces that may
threaten the development and implementation of the OMC, and to support the changing
phase of Lewin’s Change Theory, multiple educational sessions were done to inform key
stakeholders, including PCPs and organization leadership, of the growing problem of
opioid abuse among patients on chronic opioid therapy and the need for an intervention to
address this problem. In the refreezing phase, findings from the evaluation of the OMC
were reported to leadership and PCPs to illustrate the effectiveness of the OMC in
identifying abuse and misuse of opioids, and in improving PCP satisfaction in managing
patients at high risk for opioid abuse.
Dissemination and Utilization of the Results
The development of the OMC in VA Las Vegas was initiated by an APRN using
Lewin’s Change Theory as a theoretical framework to garner support for the
implementation of the OMC project. The OMC was implemented in the VA Las Vegas
in July 2013. From November 2013 through February 2014, the OMC was evaluated
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using an IRB approved protocol to evaluate effectiveness. Findings from these
evaluations have shown success in meeting the objectives of the OMC. The evaluation
has shown improved compliance among PCPs in VA Las Vegas in following the
recommendations from the VA/DoD clinical practice guideline. This data was supported
by the survey finding of improved compliance in following the recommendations from
the VA/DoD clinical practice guideline and by the increase in the number of urine drug
screens ordered in the VA Las Vegas. The evaluation of the OMC also showed the
effectiveness of the OMC in identifying patients who abuse and misuse their opioid
prescriptions.
The OMC is a clinic specific to the needs of the PCPs in the VA Las Vegas and
may not be representative of other primary care clinics in the VA nationwide. However,
the findings in the evaluation of the OMC provide support for a specialized clinic that can
assist clinicians in the management of complicated and high risk patients. The OMC is a
specialized clinic similar to other specialty clinic like endocrine or oncology where
patients with certain characteristics or diseases can be referred by their primary care
providers to help better manage their patients and to improve outcomes.
The findings from the formative evaluation of the OMC were reported to the VA
Las Vegas leadership including the Director of VA Las Vegas, Chief of Staff, Nurse
Executive, and Chief of Primary Care. A plan to report the one year summative
evaluation of the OMC to leadership of VA Las Vegas for future expansion of the clinic
will also be conducted. Currently, the OMC has already secured approval from the Chief
of Primary Care for the addition of a pain psychologist in the OMC and the addition of
the Shared Medical Appointment (SMA) model as an appointment option for patients. In
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this group medical appointment model, patients interested in attending a group medical
appointment in the OMC would be scheduled an appointment in a group setting where
their needs for timely renewal of opioids as well as monitoring of their opioid therapy
would be met in a group setting. This addition of the SMA would allow more patients to
be seen and evaluated in the OMC by eliminating the structured 30 per patient
appointment slots and allow multiple patients to be seen in a two-hour group medical
appointment slots. The implementation of the SMA into the OMC is scheduled to be
implemented on April 29, 2014.
The development, implementation, and evaluation of the OMC based on Lewin’s
Change Theory allowed for structured and evidence-based phases to take place which
resulted in the overall achievement of the objectives of the OMC project. The
development of the OMC was aligned to the needs of the PCP based on the needs
assessment survey. The implementation of the OMC was aligned with the VA/DoD
clinical practice guideline to ensure evidenced-based strategies that would identify abuse
and misuse of opioids among patients. The evaluation of the OMC was aligned to the
objectives of the OMC project and in evaluating the outcomes of the OMC against these
project objectives. These strategic phases in the development and implementation of the
OMC can be of assistance to others who may be looking for a strategy to help address the
opioid abuse problems in the United States. It is therefore important that the strategic
phases in the development and implementation of the OMC as well as the evaluation
findings of the OMC be shared to others through publication. Among the peer-reviewed
publications that might be considered include the Federal Practitioner which is a peerreviewed journal for healthcare professionals in the VA, DoD and the public health
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service, and the Journal of Pain which publishes original articles relating to all aspects of
pain management.
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